National Biofilms Innovation Centre

Lead Research Organisation: University of Southampton

Abstract

The University of Southampton will receive the award on behalf of the lead institutions of the NBIC consortium (University of Southampton, University of Liverpool, University of Nottingham and the University of Edinburgh). The University of Southampton will also be responsible for the disbursement of funds to the lead institutions of the NBIC consortium. The Grant Holder will be Jeremy Webb (Principle Investigator, Corresponding) on behalf of the NBIC Consortium lead investigators Jeremy Webb (Southampton), Rasmita Raval (Liverpool), Cait MacPhee (Edinburgh) and Miguel Camara (Nottingham)".
Biofilms are central to some of the most urgent global challenges and exert considerable economic impact across industry sectors. They are a leading cause of antimicrobial resistance (AMR), forecast to cost $100tn in world GDP and 10m deaths by 2050. Biofilms are the major cause of chronic infections, costing the NHS £2bn p.a. Contamination, energy losses and damage by biofilms impact on the £70bn UK foods industry, the $2.8 trillion consumer products sector, and $117bn global coatings industry. Biofilm management is essential to deliver clean and globally sustainable drinking water and food security.
The National Biofilms Innovation Centre (NBIC) will deliver a future where biofilms can be effectively controlled and harnessed, increasing value for the companies we work with, and providing pathways to impact for world-class research across the UK. NBIC will bring UK companies from across the industrial sectors around the table with the best of UK biofilm research to accelerate the adoption of new technologies into company products and services. Where companies are not ready to take an opportunity to market, we will provide world class entrepreneurial training to maximise the success of our spin outs
NBIC will provide a focus for industry partners to access biofilm research across the UK, simplifying knowledge transfer and catalysing collaboration. Working with industry, NBIC will produce sector roadmaps, identifying the unmet needs of the sectors, and the key scientific, commercial, technical and regulatory barriers to meet them. The roadmaps will provide a key context for the evolution of the NBIC science strategy.
NBIC will leverage existing investments in research, facilities and people to address near and long term industrial and societal challenges and to establish a pathway for the accelerated adoption of new biofilm innovations and technologies, whilst significantly promoting the expansion of a highly trained researcher workforce in this field.
We will develop the next generation of leaders in biofilms with bespoke scientific, entrepreneurial and leadership training, and we will undertake International exchanges of students and staff with SCELSE biofilms centre in Singapore. We will engage with all of the university doctoral colleges with a view to submitting a bid to the 2019 DTP call.
We will draw on the considerable outreach and engagement experience of the NBIC partners to share and develop tailored events and activities suitable for primary and secondary schools, CPD for teachers, science festivals, youth groups and community-based organisations throughout the UK.

Technical Summary

Technical Summary
NBIC will work across 4 strategic themes to prevent, detect, manage and engineer biofilms, capitalising on world-class underpinning research to address sectoral challenges identified with our industry partners. NBIC will work with industry, regulators, funders and policymakers, and engage the public in a two-way dialogue to refine the research and industrial strategy agenda, shape public funding initiatives and determine strategy for industrial pre- and post-competitive research.
The strategy and remit of the 4 themes are as follows:
PREVENT: Prevention of early stage microbial adhesion and colonisation events at surfaces. Advanced techniques to create next-generation biofilm prevention strategies.
DETECT: Accurate, quantitative biofilm detection and metrology across multiple scales through innovative sensing, tracking and diagnostic technologies. Identify and exploit new and known biofilm-specific biomarkers.
MANAGE: To kill, remove or control established biofilms by understanding and exploiting their life cycle dynamics and development across a range of environments and levels of complexity.
ENGINEER: Harness the benefits of complex microbial consortia from knowledge of their composition, function, ecology and evolution. Exploit biofilm understanding at the interface with engineering and process applications.
CROSS-CUTTING THEME: PREDICTIVE MODELLING. This theme will exploit our expertise in computational and mathematical tools for understanding, modelling and simulating biological and physical processes and activities of biofilms.
By addressing the scientific challenges and strategy outlined above, NBIC will help companies create value by benefiting from biofilms or by addressing the challenges that they face caused by biofilms.

Planned Impact

Impact summary

The National Biofilms Innovation Centre will bring together academic researchers from multiple disciplines; facilitate existing academic/industry collaborations where relevant and appropriate; broker new interactions between the academic research base and industry; and draw upon world-class underpinning bioscience to address unmet industry needs. NBIC will create the world's premier centre for biofilms training and research, and ensure its translation into capacity building and innovation.

NBIC will engage with industry by facilitating knowledge integration and capacity building. NBIC will be a single point of call for companies with challenges that relate to biofilm technologies, whether the challenge is to prevent (e.g. in human health applications), detect (e.g. in potable water systems), manage (e.g. in wastewater treatment plants) or engineer (e.g. in industrial biotechnology applications). Given this wide field of potential sectors, NBIC will draw on and facilitate links with all relevant disciplines across the physical, life, medical and social sciences. The goal is bidirectional: to ensure the maximum impact of world-class underpinning science, as well as respond directly to unmet industry needs. NBIC will achieve this by: establishing sector-specific roadmaps to educate and influence the academic base; the allocation of joint academic/industry collaborative funding; provision of entrepreneurial training for early career researchers and established academics; and the organisation of multiple different types of events, all designed to enrich relationships between Universities and companies.

Market analysis indicates that the formation, control, removal or use of biofilm technology has a global impact on economic activity of $5,000bn. Fundamental scientific breakthroughs remain to be made, and the purpose of NBIC is to form a UK-wide collaborative community best able to make these breakthroughs, and ensure their translation into products, services, devices, materials and protocols that will benefit the general public.

By delivering a coherent national response to the challenges in biofilms research, NBIC will increase the efficiency and impact of the research across the UK for all the academics that work with it.

We will create value for the companies we work with by placing at the heart of our research strategy, solving their problems and helping them access new opportunities.

By providing companies and society with new tools to prevent, detect, manage and engineer biofilms we will significantly reduce the harm that they cause and improve clinical outcomes from persistent infections and biofilm related disease.

We will develop the next generation of leaders in biofilms with bespoke scientific, entrepreneurial and leadership training, and we will undertake International exchanges of students and staff with SCELSE biofilms centre in Singapore. We will engage with all of the university doctoral colleges with a view to submitting a bid to the 2019 BBSRC DTP call.

We will draw on the considerable outreach and engagement experience of the NBIC partners to share and develop tailored events and activities suitable for primary and secondary schools, CPD for teachers, science festivals, youth groups and community-based organisations throughout the UK.

Organisations

Publications

10 25 50

publication icon
Allen RJ (2019) Bacterial growth: a statistical physicist's guide. in Reports on progress in physics. Physical Society (Great Britain)

 
Title #BiofilmAware social media assets 
Description Social media assets and headers to help raise awareness of what biofilms are and why they are so important and to promote the #BiofilmAware campaign. 
Type Of Art Artwork 
Year Produced 2020 
Impact Social media assets and headers to help raise awareness of what biofilms are and why they are so important and to promote the #BiofilmAware campaign. 
URL https://www.biofilms.ac.uk/biofilmaware/
 
Title #BiofilmWeek social media assets 
Description Social media assets and headers to help raise awareness of what biofilms are and why they are so important and to promote #BiofilmWeek, an initiative which is part of the #BiofilmAware campaign. 
Type Of Art Artwork 
Year Produced 2021 
Impact Social media assets and headers to help raise awareness of what biofilms are and why they are so important and to promote #BiofilmWeek, an initiative which is part of the #BiofilmAware campaign. 
URL https://www.biofilms.ac.uk/biofilmweek/
 
Title A New Weapon Against Pseudomonas aeruginosa, with Bhavik Bharochia from the University of Southampton. 
Description Video explaining biofilm research and societal impact. 
Type Of Art Artefact (including digital) 
Year Produced 2021 
Impact Public engagement. 
URL https://www.biofilms.ac.uk/pseudomonas-aeruginosa-a-new-weapon/
 
Title Antibiotic Resistance in Skin Wound Infections, with Snehal Kadam from the University of Hull. 
Description Video explaining biofilm research and societal impact. 
Type Of Art Artefact (including digital) 
Year Produced 2021 
Impact Public engagement. 
URL https://www.biofilms.ac.uk/antibiotic-resistance-infections/
 
Title Article and drawing produced by primary school children (J C Denis) 
Description 2 P7 children wrote and article and produced a drawing of the Edinburgh NBIC PI, following a series of events I organised. 
Type Of Art Artwork 
Year Produced 2020 
Impact Very high quality science interview produced. 
URL https://blogs.ed.ac.uk/physics-astronomy/2020/09/21/interview-with-cait-macphee/
 
Title Battling Bacterial Vaginosis, with Ryan Kean from Glasgow Caledonian University. 
Description Video explaining biofilm research and societal impact. 
Type Of Art Artefact (including digital) 
Year Produced 2021 
Impact Public engagement. 
URL https://www.biofilms.ac.uk/bacterial-vaginosis/
 
Title Biofilm Brainhub website 
Description The Biofilm Brainhub was funded by the National Biofilms Innovation Centre (NBIC) Public Engagement Grant 2020-2021. 
Type Of Art Artistic/Creative Exhibition 
Year Produced 2021 
Impact The website has been built with the support of the wider research community and features information on biofilms for a wide range of publics, through multiple clickable layers of information. We hope this will be the "go-to website" for anyone looking to learn about biofilms. 
URL https://biofilmbrainhub.co.uk/
 
Title Biofilm Embroidery series 
Description Series of 4 pieces of embroidery depicting biofilms as imagined by embroiderer: Ruby Tait Collaboration: Jean-Christophe Denis 
Type Of Art Artwork 
Year Produced 2022 
Impact Embroiderer submitted embroidery as part of the NBIC Art Competition - and won. Alos, to be displayed at exhibition in 2023. 
 
Title Biofilm Image Gallery 
Description In January 2021 we launched our first biofilm photography competitions as part of our #BiofilmAware campaign, which works to raise awareness of NBIC and its research, and the many societal and economic impacts of biofilms. 
Type Of Art Artwork 
Year Produced 2021 
Impact This biofilm image gallery contains a selection of images from our 'Biofilms in the lab' and 'Biofilms in Real Life' photography competitions. 
URL https://www.biofilms.ac.uk/biofilm-image-gallery/
 
Title Biofilm, Mutants and Mass Spectrometry, with Winifred Akwani from the University of Surrey. 
Description Video explaining biofilm research and societal impact. 
Type Of Art Artefact (including digital) 
Year Produced 2021 
Impact Public engagement. 
URL https://www.biofilms.ac.uk/mass-spectronomy-biofilm/
 
Title Bioiflms animation video. (J C Denis) 
Description Animation movie to describe the biofilms research in Edinburgh. 
Type Of Art Film/Video/Animation 
Year Produced 2020 
Impact Animation movie to describe the biofilms research in Edinburgh. 
URL https://youtu.be/-MpueLFcC1I
 
Title Biological Photovoltaics and Sustainability, with Maira Anam from the University of Nottingham. 
Description Video explaining biofilm research and societal impact. 
Type Of Art Artefact (including digital) 
Year Produced 2021 
Impact Public engagement. 
URL https://www.biofilms.ac.uk/biological-photovoltaics-and-sustainability/
 
Title Coccus Pocus 2019 
Description Antibiotic resistance by pathogenic microorganisms is currently a major health concern, leading to a big rise of serious untreatable infections, especially in hospital environments. In addition, biofilms (slimy structures that microbes form around them) further protect the microbes against antibiotics, detergents and the attacks of our immune system. In October 2019, the Department of Biomedical and Forensic Sciences at the University of Hull launched an exciting scary story competition, Coccus Pocus 2019! The contestants were encouraged to write a short horror sci-fi story between 500 and 2,000 words, including antimicrobial resistance and microbial biofilms. 
Type Of Art Creative Writing 
Year Produced 2019 
Impact Prizes were awarded for first, second and third places with the stories being published on the NBIC website. 
URL https://www.biofilms.ac.uk/coccus-pocus-2019-a-microbiology-inspired-scary-story-competition/
 
Title Coccus Pocus 2020 
Description A horror sci-fi short story competition highlighting the importance of antibiotic resistance and biofilms. In an ambitious attempt to inform young people about the importance of antibiotic resistance and microbial biofilms, we will organise a horror sci-fi short story competition for this Halloween. The participants will be encouraged to write an engaging scary story, incorporating valid scientific information about AMR and biofilms. This will motivate them to read about these topics, understand the basic principles and use this information in their post-apocalyptic horror scenarios, in an educational and enjoyable way. 
Type Of Art Creative Writing 
Year Produced 2020 
Impact Prizes were awarded for first, second and third places with the stories being published on the NBIC website. 
URL https://www.biofilms.ac.uk/coccus-pocus-2020-halloween/
 
Title Coccus Pocus 2021 
Description A horror sci-fi short story competition highlighting the importance of antibiotic resistance and biofilms. In an ambitious attempt to inform young people about the importance of antibiotic resistance and microbial biofilms, we will organise a horror sci-fi short story competition for this Halloween. The participants will be encouraged to write an engaging scary story, incorporating valid scientific information about AMR and biofilms. This will motivate them to read about these topics, understand the basic principles and use this information in their post-apocalyptic horror scenarios, in an educational and enjoyable way. 
Type Of Art Creative Writing 
Year Produced 2021 
Impact Prizes were awarded for first, second and third places with the stories being published on the NBIC website. 
URL https://www.biofilms.ac.uk/coccus-pocus-2021-winning-stories
 
Title Combatting Cystic Fibrosis, with Declan Power from the University of Southampton. 
Description Video explaining biofilm research and societal impact. 
Type Of Art Artefact (including digital) 
Year Produced 2021 
Impact Public engagement. 
URL https://www.biofilms.ac.uk/cystic-fibrosis/
 
Title Complex Polymicrobial Biofilms, with Shaun Robertson, from the University of Nottingham. 
Description Video explaining biofilm research and societal impact. 
Type Of Art Artefact (including digital) 
Year Produced 2021 
Impact Public engagement. 
URL https://www.biofilms.ac.uk/complex-polymicrobial-biofilms/
 
Title Edinburgh Science Festival: Sherlock Holmes and the Biofilms Mystery 
Description Online activity pack: Sherlock Holmes needs your help to discover who broke into his apartment and why they did it! Can you use the clues to solve the mystery of the burglar? Use the clues and information provided about biofilms to find out WHO broke into Sherlock's apartment. 
Type Of Art Artistic/Creative Exhibition 
Year Produced 2021 
Impact Public engagement. 
URL https://storymaps.arcgis.com/stories/83be7dc3978d48f1932760c034f5afcf
 
Title Forming Biofilms Within 3D Environments, with Eirini Velliou from University College London. 
Description Video explaining biofilm research and societal impact. 
Type Of Art Artefact (including digital) 
Year Produced 2021 
Impact Public engagement. 
URL https://www.biofilms.ac.uk/biofilms-within-3d-environments/
 
Title Girlguiding Dundee/WCAIR Virtual Sleepover: Science Camp! (Nicola Stanley-Wall) 
Description PEOPLE INVOLVED: A co-development between WCAIR researchers, the Girlguiding Dundee committee, and 2 senior female scientists from SLS WHAT WAS IT? A series of activity packs released over the course of a weekend to create the feeling of a sleepover. The packs were accompanied by a series of videos, a Teams Live event, and interaction on social media, particularly using a Facebook group 
Type Of Art Artefact (including digital) 
Year Produced 2021 
Impact KEY OUTCOMES: 1600 people from across the UK signed up to take part, and the packs received over 6000 downloads. We had an incredibly busy weekend with thousands of images uploaded onto the Facebook group, and thousands of views on our YouTube videos. Well over 1000 people also signed up to receive their badge after the event. FUTURE PLANS: Continue our relationship with Girlguiding so that we can have an in-person sleepover in the future, and continue to use the resources developed for other projects, such as with Glasgow Science Centre. Quote: "Amazing range of activities and useful downloadable resources which we can use again. It was also a great way of introducing science to young people and to de-mystify it for them. So often it is taught in schools in such a dull way - excellent weekend! Virtual Sleepover attendee" 
URL https://discovery.dundee.ac.uk/en/publications/girlguiding-dundeewcair-virtual-sleepover-science-cam...
 
Title Images of Microbiology 
Description A booklet containing a series of images taken by scientists based at the University of Dundee that highlight the microbes they work with. 
Type Of Art Artwork 
Year Produced 2021 
Impact The images in the collection are part of a physical exhibition located at the Dundee Science Centre. 
URL https://discovery.dundee.ac.uk/ws/portalfiles/portal/58788913/23109_Microbe_Picture_Book_Accessible_...
 
Title Interactive Biofilm Ontology Map 
Description We have devoted time across our industrial and academic communities to understand the language and terminology of biofilms, and this has been captured as an ontology on the MindManager platform. This was developed in consultation with 80 UK researchers (in industry and research institutions/universities) to document how they talk about and describe biofilm research, problems and opportunities. 
Type Of Art Artefact (including digital) 
Year Produced 2019 
Impact Reference document to guide discussions on biofilm research, problems and opportunities. 
URL https://www.biofilms.ac.uk/biofilm-ontology/
 
Title International Biofilm Markets Infographics 
Description In the summer of 2020, we commissioned an independent study on international biofilm markets to further understand the economic significance of biofilms in the UK and globally. The study estimated expenditure associated with biofilms in 2019; information is not yet generally available for 2020 to quantify the impact of the COVID-19 pandemic. Biofilms are ubiquitous but particularly prominent in some sectors of the economy. These sectors form the focus of this study. We have used publicly available evidence to quantify economic activity relating to biofilms. The study assessed the focus industrial sectors of the National Biofilms Innovation Centre. The total economic impact was estimated to be almost $4,000bn globally and £45bn ($62Bn) in the UK. These are likely to be under-estimates of the impact of biofilms. For example, in healthcare whilst we identified $387bn of direct costs as a consequence of biofilms (5% of global healthcare expenditure). we know that prevention of infection (strongly linked to biofilm control) is a major goal of all healthcare procedures and so impacts significantly on the world's $7,800bn health related activity. We conservatively estimate the true total economic significance of biofilms is likely to be in excess of $5,000bn. We've created infographics to reflect the results of this study and show the huge impact biofilms have on our global economy. 
Type Of Art Artwork 
Year Produced 2021 
Impact These highlight key facts and statistics relating to 6 international biofilm markets - personal care, human health, food processing, marine biofouling, oral care and homecare. 
URL https://www.biofilms.ac.uk/international-biofilm-markets/
 
Title MicroBattle (µB): Microbiology themed card game 
Description MicroBattle Project was funded by the National Biofilms Innovation Centre (NBIC) Public Engagement Grant 2020-2021. MicroBattle (µB): Microbiology themed card game. 
Type Of Art Artistic/Creative Exhibition 
Year Produced 2021 
Impact Resources for members of the public to gain understanding of biofilms. 
URL https://www.biofilms.ac.uk/microbattle-card-game/
 
Title Microbe Zone (Nicola Stanley-Wall) 
Description A physical exhibition, the microbe zone, located at Dundee Science Centre features images of microbes. Scientists at the University of Dundee alongside some collaborators at other Scottish Institutions contributed images of microbes that highlight their research. Short descriptions accompany the images to allow the reader to explore the wonderful world of microbiology. An associated 'Images of microbiology' booklet and activity book have been created. 
Type Of Art Artistic/Creative Exhibition 
Year Produced 2021 
Impact New publications and new recognition of research using microbiology. 
 
Title Mighty Microbe 
Description A video of NBIC partner Katherine Fish, a Civil Engineer at the University of Sheffield talking about how she works with microbes, and describing how to make a Mighty Microbe toy. This video was made for the Maker{Future}'s 'Think Like An Engineer' initiative, funded by the Royal Academy of Engineering. 
Type Of Art Artefact (including digital) 
Year Produced 2021 
Impact Public engagement. 
URL https://www.youtube.com/watch?v=4B9_6PWA8io
 
Title Molecular Microbe-Host Interactions, with Shi-qi An from the University of Southampton. 
Description Video explaining biofilm research and societal impact. 
Type Of Art Artefact (including digital) 
Year Produced 2021 
Impact Public engagement. 
URL https://www.biofilms.ac.uk/microbe-host-interactions/
 
Title Physics x Art 
Description Art exhibition featuring work created by student artists and inspired by physics research. The exhibition featured a gallery opening with over 70 attendees from various different backgrounds (Arts, Edinburgh public, Phyiscs). The exhibition was open from Friday, 14 October - Tuesday, 18 October which included a wider audience of passers-by, art students, College of Science and Engineering students, Edinburgh public. It also included outreach activities ('Build your own Biofilm). Featured art and sculptures related to biofilms (along with other projects). NBIC Collaborators: Jean-Christophe Denis; Cait MacPhee. 
Type Of Art Artistic/Creative Exhibition 
Year Produced 2022 
Impact Closer cooperation with Edinburgh College of Arts. Art will be displayed in a new building of the University of Edinburgh, The Nucleus, during its official opening by Princess Anne and viewable pubilcally then. 
 
Title Raman Against Respiratory Infection, with Callum Highmore from the University of Southampton. 
Description Video explaining biofilm research and societal impact. 
Type Of Art Artefact (including digital) 
Year Produced 2021 
Impact Public engagement. 
URL https://www.biofilms.ac.uk/raman-respiratory-infection/
 
Title Safeguarding Water Quality for the Future, with Katherine Fish from the University of Sheffield. 
Description Video explaining biofilm research and societal impact. 
Type Of Art Artefact (including digital) 
Year Produced 2021 
Impact Public engagement. 
URL https://www.biofilms.ac.uk/water-quality/
 
Title Scales of Resistance video (Morgan Alexander) 
Description A short video presentation providing educational information regarding the issue of antibiotic resistance and the need to take effective action in the future. 
Type Of Art Film/Video/Animation 
Year Produced 2019 
Impact Used as part of the Royal Society Summer Science Online programme promoting science to the general public. Morgan Alexander. 
URL https://cfvod.kaltura.com/p/1355621/sp/135562100/thumbnail/entry_id/1_y72nz7d1/version/100001/width/...
 
Title Science Ceilidh 
Description Science Ceilidh-biofilms formation, shows how microbiomes formed into biofioms. 
Type Of Art Performance (Music, Dance, Drama, etc) 
Year Produced 2018 
Impact It allows participants and viewers to have a more direct understanding of biofilms formation and how they are different from normal individual microbiomes, and how physics might be able to tackle the issue. 
URL http://www.scienceceilidh.com/physics
 
Title Science For All Takes Many Hands (Nicola Stanley-Wall) 
Description A common factor of many public engagement encounters is that they would not be possible without contributions from many people with diverse roles and skills. If we take the signature outreach event of the Division of Molecular Microbiology Magnificent Microbes as an example, there are 25 different groups of people involved to allow this long-standing public engagement event to achieve its goals. Illustrator Daisy MacGowan created Science For All Takes Many Hands which highlights and celebrates the breadth of the contributions from across the University of Dundee and beyond. These roles come from estate and buildings, health and safety, finance, contracts, research finance, research innovation services, cleaning services, and many more. Look at the illustration to explore the roles in more depth. It is important that we all recognise that public engagement by researchers is the result of teamwork and the collective effort is what allows success. 
Type Of Art Artwork 
Year Produced 2020 
Impact Stimulate change in scientist and public perception. The recognition that many people in divergent roles have valuable contributions to science outreach. Nicola Stanley-Wall 
URL https://discovery.dundee.ac.uk/en/publications/science-for-all-takes-many-hands
 
Title Sculptures (4) 
Description 3d Print and Resin Sculpture series (earth, europa, space, mars) of imagined biofilms - artist: Catriona Clark Collaboration: Jean-Christophe Denis; Cait MacPhee 
Type Of Art Artwork 
Year Produced 2022 
Impact Sculptures were included in an exhibition in October 2022 and will be included in an exhibition at the University of Edinburgh in 2023, at the opening of a new building, which will be officially opened by Princess Anne. 
 
Title Super biomaterials to fight superbugs (Morgan Alexander) 
Description A short animated video showing how Nottingham University are trying to find novel surface coatings that prevent superbugs sticking and building slime city communities called biofilms. 
Type Of Art Film/Video/Animation 
Year Produced 2019 
Impact Used as part of the Royal Society Summer Science Online programme promoting science to the general public. Morgan Alexander. 
URL https://cfvod.kaltura.com/p/1355621/sp/135562100/thumbnail/entry_id/1_00ytd3sg/version/100001/width/...
 
Title University of Edinburgh Biofilm Innovation website 
Description A website from the University of Edinburgh which showcases the important biofilm research taking place across the institution. The site also includes a number of educational and outreach resources available for download. 
Type Of Art Artistic/Creative Exhibition 
Year Produced 2021 
Impact A website from the University of Edinburgh which showcases the important biofilm research taking place across the institution. 
URL https://www.ed.ac.uk/edinburgh-biofilms-innovation
 
Title Unruly Objects 
Description Exhibition at Victoria and Albert Museum 24-25 September 2022 presenting the work completed during an NBIC funded public engagement and outreach project. Discover how BioArt can help mitigate climate change and join the drop-in lab to create your own tiny marble sculpture painted with 'living latex'. 
Type Of Art Artistic/Creative Exhibition 
Year Produced 2022 
Impact Unruly Objects explores ways of capturing carbon using cyanobacteria encapsulated into a kind of 'living latex' to mitigate climate change. It also investigates the possibility of conserving antiquities through the enhancement of their microbiomes, the place of BioArt within museums, and the use of blockchain technologies to store conservation data. Project developed by Anna Dumitriu in collaboration with Simone Krings, Dr. Suzie Hingley-Wilson and Professor Joseph Keddie from the University of Surrey. Join the Unruly Objects Lab to create your own tiny marble 'unruly objects' painted with 'living latex' and keep your tiny sculpture or leave it with us to become part of a new BioArt work. Activity open to adults and children (5+ years) accompanied with an adult. 
URL https://www.vam.ac.uk/event/4KODrMy2bB/unruly-objects
 
Title Using AI to Detect Bacteria in Wastewater, with Gavin Melaugh, from the University of Edinburgh. 
Description Video explaining biofilm research and societal impact. 
Type Of Art Artefact (including digital) 
Year Produced 2021 
Impact Public engagement. 
URL https://www.biofilms.ac.uk/using-ai-to-detect-bacteria/
 
Title Why Should I brush my teeth? 
Description Activity with the aim to Introduce biofilms in the context of teeth hygiene. Works well for attracting people at a stall, as very noticeable setup and intriguing. 
Type Of Art Artistic/Creative Exhibition 
Year Produced 2020 
Impact Used for public engagement. 
 
Description NBIC has created a pioneering and truly national centre with international reach. We have adopted an inclusive approach that has brought together the original four lead Universities (Edinburgh, Liverpool, Nottingham and Southampton), and a partnership that has expanded to include 59 associate research institutions (RIs), and support from a growing base of >150 small, medium and large companies. This has brought the UK an unprecedented set of capabilities, connectedness and exploratory power that has allowed us to be a crucible and catalyst for innovation and to achieve impact on a global stage. NBIC has created a global brand, linked to the world's leading biofilm RIs. We have signed Memoranda of Understanding (MOU) with four of these centres and are well connected with others. NBIC is proud to be recognised internationally for its innovation and leadership role in biofilms through international webinars and landmark work on defining the global research and commercial opportunity. Our impact is evidenced by our company interactions and partnering, our portfolio of 80 Proof of Concept (POC) projects, 34 Flexible Talent Mobility Awards (FTMA), and collaborative partnership awards with the USA, Singapore and Argentina. NBIC is also educating the next generation of researchers and entrepreneurs and driving the UK engine to influence the policy and research agenda for biofilms. Only via the creation of NBIC has this national connectivity and global impact been realised, hence advancing the BBSRC Biofilm strategy.
Exploitation Route NBIC will build on its collective strengths as the UK's national centre to drive and expand its global leadership at the
international forefront of research, training and innovation in biofilm technologies, addressing the grand challenges
important to the UK's future prosperity.
We will work with our partnership of 63 research institutions and >150 companies, established under Phase 1, and
transition to an approach that develops deeper and more strategic collaborations, focused and co-opted teams, and jointindustry
programs to address strategic priorities and deliver on shared sectoral roadmaps.
Key overall objectives that will be addressed during Phase 2 will be to:
- Tackle the biggest open research and innovation questions in the field and deliver global leadership, cross-cutting
enabling platforms and breakthrough science and innovation to Prevent, Detect, Manage and Engineer (PDME) biofilms.
- Drive the adoption of flexible, interdisciplinary solutions across industry sectors, addressing societal and economic grand
challenges, including climate change, NetZero, food and water safety and security, and healthcare. We will establish the
Joint Industry Programs addressing pre-competitive research to progress agreed roadmaps.
- Enter into active partnerships with government and policy makers to deliver step-changes in standards and regulations for
novel biofilm solutions. We will deliver model biofilms, analytical methods and recommendations within 3 years and support
industry-government discussions on regulation through providing a strong evidence base to underpin policy. We will
develop new international standards and test protocols driving growth and trade in biofilm products and technologies by
Year 5.
- Deliver a roadmap for new biofilm biobanking resources and infrastructure, which have been identified by our community
as critical to underpin basic science programmes as well as accelerate product development and commercialization.
- Provide global leadership via enhanced interactions with established centres in Singapore, US and the EU, while
nucleating new relationships and networks with countries with rapidly expanding economic and healthcare challenges.
- Train the next generation of thought leaders and entrepreneurs by delivering a co-created programme of training that
addresses key skills gaps identified by our industrial and academic communities.
- Accelerate the translation of knowledge-rich solutions to industry and the market via academic-industry collaborations,
and then driving innovation and growth via close engagement with regional partners, thus contributing to the 'levelling-up'
agenda. Companies that we work with will use the outputs of our work to launch new products, processes and services.
Together with our partners we will maximise the commercial impact of world-class knowledge developed by our research
and industry base to deliver economic and societal impact for the UK.
Sectors Aerospace, Defence and Marine,Agriculture, Food and Drink,Digital/Communication/Information Technologies (including Software),Education,Energy,Environment,Healthcare,Government, Democracy and Justice,Manufacturing, including Industrial Biotechology,Culture, Heritage, Museums and Collections,Pharmaceuticals and Medical Biotechnology,Transport

URL http://www.biofilms.ac.uk
 
Description The vision for the National Biofilms Innovation Centre is to create a fusion of world-class research and industry to deliver breakthrough technologies in the control and exploitation of biofilms. By harnessing our interdisciplinary expertise and infrastructure across the UK, we will create the next generation of researchers and entrepreneurs to deliver growth and wealth creation. We are creating a pioneering and truly national centre, with an inclusive strategy that has brought together the original four lead Universities, a partnership that has expanded to include 63 associate research organisations, and support from a growing base of >200 small, medium and large companies. This brings an unprecedented set of capabilities, connectedness and exploratory power that carries a huge potential for innovation that will allow us to lead on a global stage. NBIC is creating a global brand, intimately linked with the world's leading biofilm research institutions. We have signed a Memoranda of Understanding (MOU) with three of these centres. NBIC aims to be recognised internationally for its innovation and collaborative research in biofilms. Our early impact is evidenced by our company interactions, partnering, our portfolio of 81 Proof of Concept (POC) projects, and workshops. We are also educating the next generation of researchers and entrepreneurs and starting to drive the policy and research agenda for biofilms in the UK. Our vision for advancing biofilm research and skills training builds on the strategic themes of Prevention, Detection, Managing and Engineering of biofilms. Together with our academic and industry partners, we are working to define the key global challenges and scientific priorities within these themes, and we will continue to refine and develop our objectives according to industry needs. We have built a UK-wide cohort of Interdisciplinary Research Fellows (IRFs) to deliver on these scientific priorities. Key challenges defined within these themes include: In Prevention we aim to design a new generation of surfaces and materials to prevent microbial adhesion and/or biofilm formation; in Detection to deliver a step change in the ability to detect biofilms directly, in-situ and at the point-of-use in field-based contexts and in close-to-patient care; in Manage to accelerate the development of successful treatments, which target the biofilm life cycle-dynamics; and in Engineer to harness the benefits of complex microbial consortia from knowledge of their composition, function, ecology and evolution. Our vision is for NBIC to be the natural route for organisations to target their open innovation activity related to biofilm management or exploitation across the UK. We are connecting experts, simplifying knowledge transfer and catalysing collaboration to address key issues on biofilm prevention, detection, management and engineering. Working with industry, NBIC is already starting to produce sector roadmaps, identify the unmet needs of the sectors, and the key scientific, commercial, technical and regulatory barriers to meet them. The roadmaps will provide clear direction to evolve the NBIC science strategy over time. Our vision is that the research institutions in NBIC will create and share the national infrastructure that UK industry needs and that NBIC will collaborate with companies across a wide range of sectors under a permissive IP framework that anchors IP within the team that creates it, and rewards increasing commitment from companies. We have built this approach to IP into our contracts for our POC calls. Through site visits and discussions, we are building an understanding of the capabilities of all our partner research institutions to be able to capture current infrastructure and begin to identify gaps. A key part of our vision is to transform the research and entrepreneurial capability across the UK in the biofilm community through our IRFs, Doctoral Network and entrepreneurial training, addressing the skills gap in multidisciplinarity, entrepreneurship, responsible innovation, regulatory knowledge and leadership identified across the multi-sectorial biofilm field. The NBIC vision is one we have shared widely through our face-to-face contact with researchers, engagement with companies, our communications, consultations, workshops and social media. Our wider vision has been refined in response to the views of the wider community and through input from our Advisory Groups. A clear measure of the community support we have for this vision is the active and firm support from the UK Research and industrial base via their direct engagement in our work.
First Year Of Impact 2017
Sector Aerospace, Defence and Marine,Agriculture, Food and Drink,Chemicals,Communities and Social Services/Policy,Construction,Education,Energy,Environment,Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology,Transport
Impact Types Societal,Economic,Policy & public services

 
Description Active participation in the International Biofilm Standards Task Group (Paulina Rakowska)
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
URL https://www.biofilms.ac.uk/international-standards-task-group/
 
Description Approaches to Biofilm-associated Infections: Evaluating Gaps in Standardized Methods for Clinical Applications. Credits for continuing education webinar. (Paul Stoodley)
Geographic Reach North America 
Policy Influence Type Influenced training of practitioners or researchers
URL https://education.healthtrustpg.com/calendar/2454/2020-06-21/
 
Description Attendance at policy / strategy meeting with BBSRC to influence and contribute to the Microbiome Research Strategy (Mark Richardson) (Jan - Mar 2020)
Geographic Reach National 
Policy Influence Type Participation in a guidance/advisory committee
Impact Attendance at policy / strategy meeting with BBSRC to influence and contribute to the Microbiome Research Strategy.
 
Description BBSRC Microbiome Research Strategy (Jeremy Webb) (Jan - Mar 2020)
Geographic Reach National 
Policy Influence Type Participation in a guidance/advisory committee
Impact Attendance at policy / strategy meeting with BBSRC to influence and contribute to the Microbiome Research Strategy.
 
Description Board Member, Audit and Risk committee and EPSRC Value for Money committee, Rosalind Franklin Institute (Peter Smith)
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Membership of a guideline committee
Impact Formation of a new national research institute working at the interface of life sciences and engineering.
 
Description Citation in a clinically-focused review (Dario Carugo)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical reviews
URL https://turkishjournalofurology.com/en/problems-and-solutions-of-stent-biofilm-and-encrustations-a-r...
 
Description Co-supervise a PhD candidate (Peng Bao)
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
Impact Kyle has trained for the use of multiple instruments. He has gone to Bruker (Berlin) for an on-site training on BioAFM. Kyle has progressed well with his PhD study and he has built a solid research plan.
 
Description Cosmetics Cluster UK Ltd (Katerina Steventon)
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact Via organising the joint webinar(s), NBIC enabled CCUK members to access new academic and industry expertise, and gain better understanding of market trends, claim substantiation and regulatory insights in the area of microbiome in personal care. The collaboration also informed CCUK about NBIC remit, initiatives and approach to innovation, to share this knowledge widely.
URL https://www.youtube.com/watch?v=js3SF_j2zlo
 
Description Cystic Fibrosis Syndicate in AMR (Mark Richardson)
Geographic Reach Multiple continents/international 
Policy Influence Type Contribution to a national consultation/review
Impact To address these challenges, the CF Syndicate in AMR will catalyse new research efforts and build capacity in the following areas: Streamline and enable access to clinically relevant samples for the preclinical screening and testing of CF antimicrobials Map and validate the preclinical screening and testing pathways to provide faster routes to bring CF antimicrobials to the clinic Develop guidance for industry on the key characteristics and requirements that CF antimicrobials should meet in order to address the needs and priorities of people with CF, through the development of Target Product Profiles.
URL https://md.catapult.org.uk/syndicates/cystic-fibrosis-syndicate-in-antimicrobial-resistance/
 
Description Cystic Fibrosis Syndicate on AMR with the Cystic Fibrosis Trust and Medicines Discovery Catapult Syndicate Steering committee (Miguel Camara)
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
Impact We have designed a strategy to accelerate the discovery, commercialisation and implementation of novel therapeutic approaches for patients with cystic fibrosis. I am representing NBIC within this committee. We are working on the generation of strain biobanks for patients, Target Products Profiles for CF and drug discovery platforms which can be accessible to the general scientific and industrial community.
 
Description EPSRC Beyond Antibiotics International advisory board (Paul Stoodley)
Geographic Reach National 
Policy Influence Type Participation in a guidance/advisory committee
 
Description Formation of the International Biofilm Standards Task Group with our partners at CBE and SNBC (Jeremy Webb and Mark Richardson)
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
URL https://www.biofilms.ac.uk/international-standards-task-group/
 
Description IBRG (INTERNATIONAL BIODETERIORATION RESEARCH GROUP) Advisory Committee (Mark Richardson)
Geographic Reach National 
Policy Influence Type Participation in a guidance/advisory committee
Impact Membership of this group has allowed me alongside our IBSTG membership to demonstrate that NBIC is well engaged with the wider biofilm sector and allowed me to gain membership and chairmanship of a BSI technical advisory group.
URL https://www.ibrg.org/Default.aspx
 
Description Invited to UK-Singapore strategic talks representing global NBIC-SCELSE partnership. Government-to-Government discussions involving FCO, BEIS, Innovate UK, NRF (Jeremy Webb)
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Involvement in the KTN Special interest group on the Microbiome across multiple sectors to aid in support of business progress and academic translation. (Mark Richardson)
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Joint Research Strategy Board, University of Southampton and University Hospital Southampton (Peter Smith)
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Membership of a guideline committee
Impact Coordinating clinical, health and research activities across the University of Southampton and the University of Southampton foundation Trust.
 
Description KTN-NBIC Workshop on Biofilms and formal Report (Rasmita Raval)
Geographic Reach National 
Policy Influence Type Contribution to a national consultation/review
URL https://admin.ktn-uk.co.uk/app/uploads/2018/05/Biofilm-Workshop-Report-May2018.pdf
 
Description Local Enterprise Partnership Innovation South Strategic Regional Industrial Policy. (Peter Smith)
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a guidance/advisory committee
 
Description MedTech Market Access (Peter Smith)
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
Impact Better informed start up and SME community on the processes and pitfalls of developing a Medtech product through to deployment.
 
Description Member of the Cystic Fibrosis Trust Strategic Implementation Board (Miguel Camara)
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact Being a member of this Board I have been involved in the selection of the awards for Strategic Research Centres which are key to develop new treatments for cystic fibrosis, influencing clinical guidelines and provide training for early career researchers.
 
Description Member of the International Advisory Council for Cluster for Pioneering Research (CPR) at RIKEN, Japan (Rasmita Raval)
Geographic Reach National 
Policy Influence Type Participation in a guidance/advisory committee
URL https://www.riken.jp/en/news_pubs/pubs/reports/cpr/index.html
 
Description Methodology - The methodology used in this project can provide a quick and accurate screening method for the generation of ROS within the TAED/H2O2 system. (Claudio Lourenco)
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
URL https://discovery.ucl.ac.uk/id/eprint/10112700/
 
Description Microbiome Innovation Network Steering Group (Mark Richardson)
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
URL https://ktn-uk.org/agrifood/microbiome/
 
Description Participation in BSI CH/216/1 Standards meeting . Influencing Standards (Mark Richardson)
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
Impact NBIC on behalf of IBSTG is now on the BSI committee for reviewing antiseptic / disinfectant testing standards . This feeds in CEN, We aim to try and influence the adoption of Biofilm relevant testing in these standards.
URL https://standardsdevelopment.bsigroup.com/committees/50081157
 
Description Participation in IBBS expert panel on standards and regulations (Mark Richardson)
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
Impact This was an international webinar expert panel discussing the need for innovation in standards and regulations in a range of fields and how this could be coordinated internationally. Follow up discussions are happening.
 
Description Participation with NIBSC and MHRA on standard setting (Mark Richardson)
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
 
Description SCELSE Scientific Advisory Board
Geographic Reach Asia 
Policy Influence Type Participation in a guidance/advisory committee
 
Description SoCO BIO DTP (Mark Richardson)
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact Chairing Non Exec board of BBSRC funded DTP and able to influence the training of doctoral students.
URL https://southcoastbiosciencesdtp.ac.uk/
 
Description Society for Applied Microbiology Regulatory Standards (Jeremy Webb) (Dec 2019 - Mar 2020)
Geographic Reach National 
Policy Influence Type Participation in a guidance/advisory committee
Impact Meetings and discussions of the regulatory needs in the food environment with view to a workshop and coordinated policy of influence on regulatory standards .
 
Description Supervision of a third-year student on the course of Chem366 (Peng Bao)
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
Impact Through this course, Hamza has gained basic experimental skills, knowledge of safety rules in the lab, a better understanding of the research environment, and experience in scientific report writing and public presentation.
 
Description The Biofilm - Associated Impact of Surgical Outcomes. Continuing credit course for medical practioners. (Paul Stoodley)
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
URL https://education.healthtrustpg.com/calendar/on-demand-the-biofilm-associated-impact-on-surgical-out...
 
Description The Environmental Biotechnology Network (EBNet) Steering Group (Will Green)
Geographic Reach National 
Policy Influence Type Participation in a guidance/advisory committee
URL https://ebnet.ac.uk/
 
Description UK MoD surface fleet hull management policy
Geographic Reach National 
Policy Influence Type Contribution to a national consultation/review
 
Description UK-Singapore Bio-Institute review panel. BEIS, Innovate UK proposal for A Bio-incubator partnership with UK. (Jeremy Webb)
Geographic Reach National 
Policy Influence Type Participation in a guidance/advisory committee
 
Description University of Southampton and University Hospital Southampton Foundation Trust COVID-19 Assessment Panel (Peter Smith)
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Membership of a guideline committee
Impact Research and clinical assessment panel to fund and focus activities on the Covid-19 pandemic and possible interventions, or discouraging activity that would defocus the response.
 
Description Wessex Health Partners Working Group, Lead discovery (Peter Smith)
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Membership of a guideline committee
Impact Coordination of Wessex biomedical discovery, translation and innovation across all Universities and NHS Hospital Trusts.
 
Description Wessex Regional Life Sciences Opportunities for Enterprise (Peter Smith)
Geographic Reach National 
Policy Influence Type Implementation circular/rapid advice/letter to e.g. Ministry of Health
 
Description iiCON Infection Innovation Consortium (Rasmita Raval)
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Contribution to new or Improved professional practice
URL https://www.infectioninnovation.com/about/
 
Description A high-content screen for novel small molecules that inhibit antibiotic-resistant bacterial infection (Shi-Qi An)
Amount £20,000 (GBP)
Organisation Wessex Medical Research 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2019 
End 09/2021
 
Description A joint workshop between the UK's National Biofilm Innovation Centre and the West African Centre for Cell Biology of Infectious Pathogens
Amount £10,000 (GBP)
Funding ID BB/W018497/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 06/2022 
End 06/2023
 
Description Antibiofilm Wound Dressings Designed to Prevent Infection and Minimize the Risk of Bacteraemia and Sepsis (Ronan McCarthy)
Amount £100,000 (GBP)
Funding ID SBF006\1040 
Organisation Academy of Medical Sciences (AMS) 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2021 
End 08/2024
 
Description Assessment of Nanocin in UTI co-Biofilms (Isabelle Papandronicou)
Amount £12,000 (GBP)
Organisation University College London 
Sector Academic/University
Country United Kingdom
Start 02/2023 
End 04/2023
 
Description BBSRC Impact Acceleration Award via University of Warwick (PI) Mesoporous materials for antibiotic delivery into bacterial biofilm with industrial partner Brentapharm (Freya Harrison)
Amount £3,996 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 02/2022 
End 03/2022
 
Description BBSRC Impact acceleration award (University of Edinburgh, Gavin Melaugh, BBSRC IAA PIII089)
Amount £29,712 (GBP)
Funding ID BBSRC IAA PIII089 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 05/2021 
End 02/2022
 
Description Benchmarking different antibacterial technologies using an oral in vitro system (Jeremy Webb)
Amount £160,000 (GBP)
Organisation Unilever 
Sector Private
Country United Kingdom
Start 12/2017 
End 11/2019
 
Description Biofilm Resistant Liquid-like Solid Surfaces in Flow Situations
Amount £457,503 (GBP)
Funding ID EP/V049615/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 02/2022 
End 02/2025
 
Description Biofuel generation from CO2 by using microbial electrolysis system (Loughborough University, Eileen Yu)
Amount ¥100,000 (CNY)
Organisation Dalian National Laboratory for Clean Energy 
Sector Public
Country China
Start 01/2020 
End 12/2021
 
Description COLLABORATIVE TRAINING PARTNERSHIPS (CTP2)
Amount £7,025,368 (GBP)
Funding ID BB/W009374/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 09/2022 
 
Description DNA based super-resolution microscopy for bacterial cell surface nanoscale mapping
Amount £11,920 (GBP)
Funding ID IES\R2\222107 
Organisation The Royal Society 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2022 
End 10/2024
 
Description Developing stochastic models of micro-plastic associated biofilm growth (Miguel Camara)
Amount £6,306 (GBP)
Organisation University of Cassino and Southern Lazio 
Sector Academic/University
Country Italy
Start 03/2019 
End 08/2019
 
Description Development and validation of biofilm model to establish the effect of chemical and physical treatments on cellular viability (Miguel Camara)
Amount £12,457 (GBP)
Organisation Melbec Microbiology Ltd 
Sector Private
Country United Kingdom
Start 02/2021 
End 01/2023
 
Description Development of a Moving Membrane Bioreactor (MMBR) for the Automated Cultivation and Harvest of Algae Grown as a Biofilm (Felix Ciceron)
Amount £135,333 (GBP)
Organisation Plymouth Marine Laboratory 
Sector Academic/University
Country United Kingdom
Start 05/2019 
End 08/2022
 
Description Development of outreach material for Nottingham NBIC outreach and public engagement (Miguel Camara)
Amount £2,000 (GBP)
Organisation University of Nottingham 
Sector Academic/University
Country United Kingdom
Start 12/2018 
End 04/2019
 
Description Development of outreach material for Nottingham NBIC outreach and public engagement - Nottingham University Institute of Policy and Engagement
Amount £2,000 (GBP)
Organisation University of Nottingham 
Sector Academic/University
Country United Kingdom
Start 12/2018 
End 04/2019
 
Description Development of rapid testing technology to increase food security (Callum Highmore)
Amount £249,905 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 09/2020 
End 06/2021
 
Description Development of synthetic biofilm for calibrating the effect of coatings on reducing marine viscoelastic drag. (University of Southampton, Paul Stoodley)
Amount £87,500 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 08/2019 
End 08/2022
 
Description Direct Industrial Funding (Robin Thorn)
Amount £200,000 (GBP)
Organisation Creo Medical Ltd 
Sector Private
Country United Kingdom
Start 02/2021 
End 02/2022
 
Description Does irrigating chronic wounds with a liquid acoustic stream (LAS) improve healing?
Amount £20,800 (GBP)
Organisation Southampton NIHR Biomedical Research Centre in Nutrition 
Sector Public
Country United Kingdom
Start 01/2020 
End 06/2021
 
Description EMBO BACNET21 Conference (Nicola Stanley-Wall)
Amount € 35,000 (EUR)
Organisation European Molecular Biology Organisation 
Sector Charity/Non Profit
Country Germany
Start 09/2021 
End 09/2022
 
Description EMBO Bacterial Networks conference grant
Amount £32,795 (GBP)
Funding ID w21/22 
Organisation European Molecular Biology Organisation 
Sector Charity/Non Profit
Country Germany
Start 06/2022 
End 12/2022
 
Description EMBO LONG TERM FELLOWSHIP (University of Dundee, Nicola Stanley-Wall, ALTF 471-2020)
Amount £185,189 (GBP)
Funding ID ALTF 471-2020 
Organisation European Molecular Biology Organisation 
Sector Charity/Non Profit
Country Germany
Start 06/2020 
End 06/2022
 
Description EPSRC DTP Early Career Researcher Competition, Understanding Microbiological Risks of Urban Flooding (University of Edinburgh, Isabel Doutelero)
Amount £80,000 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 09/2020 
End 05/2024
 
Description EPSRC IAA - Anti-Viral Surfaces and Materials
Amount £20,000 (GBP)
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 03/2020 
End 10/2020
 
Description EPSRC Impact Acceleration Account (IAA) (Susana Direito 2022)
Amount £1,980,071 (GBP)
Funding ID EPSRC IAA PIV078 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 03/2022 
End 06/2022
 
Description EPSRC Impact Acceleration Account (IAA) Antimicrobial Contact Lens Cases (Raechelle D'Sa)
Amount £15,000 (GBP)
Funding ID EP/R511729/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 09/2018 
End 07/2019
 
Description EPSRC Impact Acceleration Account (IAA) Plasma activated aerosols for on-demand rapid sanitisation (Heather Allison)
Amount £14,678 (GBP)
Funding ID EPSRC IAA 2020 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 03/2020 
End 10/2020
 
Description EPSRC Impact Acceleration Account (University of Edinburgh, Susana Direito, EPSRC IAA PIII008)
Amount £16,615 (GBP)
Funding ID EPSRC IAA PIII008 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 03/2018 
End 09/2018
 
Description EPSRC Impact Acceleration Account - Anti-Viral Surfaces and Materials
Amount £20,000 (GBP)
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 03/2020 
End 10/2020
 
Description EPSRC Impact Acceleration Account, Travel and Events Funding (University of Edinburgh, Susana Direito, EPSRC lAA Pll!063 Direito)
Amount £2,304 (GBP)
Funding ID EPSRC lAA Pll!063 Direito 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 06/2019 
End 11/2019
 
Description Establishment of Cryo-EM Screening Facility At University Of Dundee (Nicola Stanley-Wall)
Amount £1,000,000 (GBP)
Funding ID 223816/Z/21/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2021 
End 12/2026
 
Description Evaluation of a stabilised hypochlorous for decontamination of root canal surfaces (Heather Allison)
Amount £45,000 (GBP)
Organisation Dentosafe-T LTD 
Sector Private
Country United Kingdom
Start 08/2018 
End 01/2019
 
Description FELS Knowledge Exchange and Enterprise Funding Skin Health and Mental Health/Wellbeing: A Cross-Functional Workshop and Structured Industry Interviews (Katerina Steventon)
Amount £12,600 (GBP)
Organisation University of Southampton 
Sector Academic/University
Country United Kingdom
Start 03/2022 
End 07/2022
 
Description Formulated Materials for Infectious Disease Prevention
Amount £3,300,000 (GBP)
Organisation European Commission 
Department European Regional Development Fund (ERDF)
Sector Public
Country Belgium
Start 07/2020 
End 07/2023
 
Description Formulated Materials for Infectious Disease Prevention (Rasmita Raval)
Amount £3,300,000 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 07/2020 
End 07/2023
 
Description Global Challenges Research Fund (GCRF) - Antimicrobial point of use water filtration in India (Raechelle D'Sa)
Amount £76,676 (GBP)
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 03/2020 
End 06/2021
 
Description Global Challenges Research Fund (GCRF) - Point of use water filtration (Raechelle D'Sa)
Amount £20,000 (GBP)
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 09/2018 
End 03/2019
 
Description ICURe Innovation to Commercialisation of University Research Cohort 40 biofilms sprint - Exploit Phase 2
Amount £11,958 (GBP)
Organisation University of Nottingham 
Sector Academic/University
Country United Kingdom
Start 09/2022 
End 03/2023
 
Description Impact Acceleration Award
Amount £19,928 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 02/2023 
End 07/2023
 
Description Impact Accelerator Account- PoC grant
Amount £74,484 (GBP)
Organisation University of Nottingham 
Sector Academic/University
Country United Kingdom
Start 01/2023 
End 12/2023
 
Description Infections in complex physical environments: Life and death in the sinuses (Bartlomiej Waclaw)
Amount £2,172,244 (GBP)
Funding ID EP/W023881/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 03/2022 
End 03/2025
 
Description Innovate UK (TS/P004512/1) (Rasmita Raval)
Amount £521,000 (GBP)
Funding ID TS/P004512/1 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 03/2017 
End 02/2019
 
Description Innovate UK TS/P013716/1 (Rasmita Raval)
Amount £350,000 (GBP)
Funding ID TS/P013716/1 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 03/2017 
End 09/2019
 
Description Innovate UK Temp Framework Aug 2020 - Anti-viral transparent adhesive protection for Touch Screens to help in the fight against COVID-19
Amount £224,011 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 12/2020 
End 08/2021
 
Description Lactam AMR Elucidating the Molecular Mechanisms of Action and Resistance of microbes to Unilever Anti-biofilm Lactam Technology
Amount £100,279 (GBP)
Funding ID BB/T509127/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 08/2019 
End 09/2023
 
Description MICRA Innovation Funding (Veeren Chauhan)
Amount £25,000 (GBP)
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 01/2020 
End 06/2021
 
Description Modulating Skin Bacteria to Improve Wound Healing in the Elderly (Holly Wilkinson)
Amount £85,000 (GBP)
Funding ID 003/S/20 
Organisation British Skin Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2022 
End 03/2025
 
Description Multifunctionalized Microalgae - A novel and flexible platform technology for maximising feed/energy conversion ratios and treating severe infections in livestock. (Michael Allen)
Amount £186,525 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 01/2019 
End 12/2021
 
Description Muscle resilience across the life course: from cells to society
Amount £184,485 (GBP)
Funding ID BB/W018284/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 02/2022 
End 01/2024
 
Description NBIC Eurobiofilms Marketing funding
Amount £6,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 08/2019 
 
Description NBIC Flexible Talent Mobility Account (FTMA)
Amount £275,000 (GBP)
Funding ID BB/S508020/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 11/2018 
End 02/2022
 
Description NIBB Summer Studentship Bursaries: Optimizing the operation of a novel photobioreactor (Mike Allen)
Amount £2,500 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 04/2021 
End 07/2021
 
Description NanoPrime (Veeren Chauhan )
Amount £2,000 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 07/2019 
End 06/2020
 
Description NanoPrime (Veeren Chauhan )
Amount £500 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 02/2020 
End 06/2020
 
Description NanoPrime Rapid (Veeren Chauhan)
Amount £5,000 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 02/2021 
End 08/2021
 
Description Nanoscale Characterisation of Biological and Bioinspired Materials using Integrated Fluidic Force - High-Resolution Confocal Microscopy
Amount £777,904 (GBP)
Funding ID BB/W019639/1 
Organisation University of Nottingham 
Sector Academic/University
Country United Kingdom
Start 07/2022 
End 07/2023
 
Description Nanoscale Characterisation of Biological and Bioinspired Materials using Integrated Fluidic Force - High-Resolution Confocal Microscopy
Amount £777,905 (GBP)
Funding ID BB/W019639/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 07/2022 
End 07/2023
 
Description National Biofilms Innovation Centre
Amount £12,801,513 (GBP)
Funding ID BB/R012415/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 12/2017 
End 11/2022
 
Description National Biofilms Innovation Centre
Amount £7,659,682 (GBP)
Funding ID BB/X002950/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 12/2022 
End 11/2027
 
Description National Biofilms Innovation Centre NBIC 2021 Flexible Talent Mobility Account
Amount £180,000 (GBP)
Funding ID BB/W510865/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 12/2021 
End 03/2022
 
Description New Testing methods for Oral care (Yuri Diaz Fernandez)
Amount £21,000 (GBP)
Organisation Unilever 
Sector Private
Country United Kingdom
Start 08/2019 
End 12/2024
 
Description Newcastle University Impact Acceleration Account - Feasibility test for large scale Microbial Electrolysis Cells (MEC) with bespoke control unit (Elizabeth Heidrich)
Amount £7,311 (GBP)
Organisation Newcastle University 
Sector Academic/University
Country United Kingdom
Start 01/2023 
End 04/2023
 
Description Nottingham DTP3
Amount £14,883,260 (GBP)
Funding ID BB/T008369/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 08/2020 
End 09/2028
 
Description Nottingham Research Fellowship (Veeren Chauhan )
Amount £300,000 (GBP)
Organisation University of Nottingham 
Sector Academic/University
Country United Kingdom
Start 09/2019 
End 09/2022
 
Description Novel Endolysin to Selectively Manage Antimicrobial Resistant S. aureus in Wound Biofilms
Amount £101,356 (GBP)
Funding ID CTP_22_0000000010 
Organisation National Biofilms Innovation Centre 
Sector Private
Start 01/2023 
End 01/2027
 
Description Novel Raman Spectroscopic Analysis for In Situ Detection of AMR in Cystic Fibrosis
Amount £15,000 (GBP)
Organisation Southampton NIHR Biomedical Research Centre in Nutrition 
Sector Public
Country United Kingdom
Start 01/2020 
End 10/2020
 
Description Partnership PhD (Robin Thorn)
Amount £227,700 (GBP)
Organisation Altered Carbon Ltd. 
Sector Private
Country United Kingdom
Start 09/2022 
End 10/2025
 
Description PhD Antibiotic resistance and biofilm formation in the WHO priority pathogen Acinetobacter baumannii (Ronan McCarthy)
Amount £84,048 (GBP)
Organisation Brunel University London 
Sector Academic/University
Country United Kingdom
Start 09/2021 
End 09/2025
 
Description PhD Developing ultrasound-responsive therapeutic agents for the treatment of chronic wounds (working title) (Dario Carugo)
Amount £90,000 (GBP)
Organisation University College London 
Sector Academic/University
Country United Kingdom
Start 09/2021 
End 10/2025
 
Description PhD Viscoelasticity and Associated-drag of Artificial and Natural Marine Fouling Biofilm (Jeremy Webb)
Amount £111,500 (GBP)
Organisation AkzoNobel 
Sector Private
Country Netherlands
Start 08/2019 
End 09/2022
 
Description Pilot screen of selected compounds versus common Gram-positive and Gram-negative bacteria (Miguel Camara)
Amount £11,689 (GBP)
Organisation Eurofarma 
Sector Private
Country Brazil
Start 03/2019 
End 07/2019
 
Description Plasma-activated antimicrobial hydrogel therapy (PAHT) for combatting infections in diabetic foot ulcers
Amount £369,080 (GBP)
Funding ID EP/V005839/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 02/2021 
End 01/2024
 
Description Product development award (PDA) scheme NIHR i4i: Can novel ureteric stents offer a better patient outcome compared to existing standard ureteric stents (CASSETTE)
Amount £1,375,896 (GBP)
Funding ID NIHR202935 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 02/2022 
End 01/2025
 
Description Proof of Concept application to the High Value Biorenewables Network (Eileen Yu)
Amount £50,000 (GBP)
Funding ID POC-HVB-2021/01 (YU) [University of York BBSRC High Value Biorenewables Network] 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 01/2022 
End 12/2022
 
Description Prophage host interactions: pulling back the curtains on Pseudomonas puppet masters (Heather Allison)
Amount £901,000 (GBP)
Funding ID BB/T015616/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 11/2020 
End 10/2023
 
Description Rapid characterisation and modelling of marine biofilm deformation for estimating biofouling frictional drag (Jinju Chen)
Amount £86,000 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 08/2022 
End 09/2026
 
Description Research Fellowship : Identification of novel antibiofilm compounds using high throughput approaches. (Miguel Camara)
Amount £63,749 (GBP)
Organisation Alfonso Martin Escudero Foundation 
Sector Charity/Non Profit
Country Spain
Start 01/2020 
End 07/2022
 
Description Research Fellowship : Role of signalling mechanisms in biofilms from uropathogenic E. coli (Miguel Camara)
Amount £107,999 (GBP)
Organisation Fundación Canaria de Investigación Sanitaria 
Sector Charity/Non Profit
Country Spain
Start 09/2019 
End 04/2021
 
Description Royal Society University Research Fellowship
Amount £1,119,000 (GBP)
Funding ID URF\R1\221795 
Organisation The Royal Society 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2022 
End 09/2027
 
Description SUrfaCe Characteristics Enabled StrategieS against virus transmission (SUCCESS)
Amount £649,501 (GBP)
Funding ID EP/V029762/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 08/2020 
End 03/2022
 
Description Seeing the virus with topological optical microscopy
Amount £180,022 (GBP)
Funding ID BB/X003477/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 08/2022 
End 03/2024
 
Description Shape, shear, search & strife; mathematical models of bacteria
Amount £361,730 (GBP)
Funding ID EP/S033211/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 08/2020 
End 08/2023
 
Description South Coast Biosciences Doctoral Training Partnership (SoCoBio DTP)
Amount £10,099,355 (GBP)
Funding ID BB/T008768/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 08/2020 
End 09/2028
 
Description Southampton AMR Clinical Research Laboratory for Antimicrobial Resistance (AMR) Capital funding. (University of Southampton, Jeremy Webb, NIHR200638)
Amount £2,859,674 (GBP)
Funding ID NIHR200638 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 11/2019 
End 10/2021
 
Description Strategic Research Centre: An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF).
Amount £773,682 (GBP)
Funding ID SRC022 
Organisation Cystic Fibrosis Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2022 
End 03/2026
 
Description Strength in Places Fund: Delivering Integrated Solutions for Human Infections. (Rasmita Raval)
Amount £18,000,000 (GBP)
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 08/2020 
End 08/2025
 
Description The State Key Laboratory Program: Understanding polybacterial interactions during rice disease (Shi-qi An)
Amount £11,000 (GBP)
Organisation Guangxi University 
Department State Key Lab for Conservation and Utilization of Subtropical Agro bioresource
Sector Academic/University
Country China
Start 12/2018 
End 12/2020
 
Description The Sustainable Innovation Fund: Optically enhanced antiviral transparent screen protection
Amount £235,709 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 09/2020 
End 06/2021
 
Description The Sustainable Innovation Fund: round 1 (temporary framework)
Amount £192,206 (GBP)
Funding ID 77477 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 08/2020 
End 06/2021
 
Description The association of biofilms to water quality deterioration in Valencia (The University of Sheffield, Isabel Doutelero)
Amount € 21,000 (EUR)
Organisation Global Omnium 
Sector Private
Country Spain
Start 09/2019 
End 10/2020
 
Description Transformative Imaging for Quantitative Biology (TIQBio) Partnership
Amount £1,626,518 (GBP)
Funding ID EP/V038036/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 03/2022 
End 03/2027
 
Description Transforming industry standards in healthcare: Connecting key UK interdisciplinary analytical platforms for biofilms across the NBIC, NPL, SCELSE and SNBC (Paulina Rakowska)
Amount £200,000 (GBP)
Organisation Department for Business, Energy & Industrial Strategy 
Sector Public
Country United Kingdom
Start 01/2021 
End 03/2021
 
Description Treatment of recurrent bacterial vaginosis using engineered probiotic bacteria
Amount £612,881 (GBP)
Funding ID BMC 10035355 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 01/2023 
End 02/2025
 
Description UKRI Ideas to address COVID-19 - Innovate UK Temp F'work Aug 2020 (University of Edinburgh, Rosalind Allen and Susana Direito, 83701)
Amount £519,283 (GBP)
Funding ID 83701 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 12/2020 
End 02/2022
 
Description UKRI Interdisciplinary Centre for Circular Chemical Economy (Loughborough University, Eileen Yu)
Amount £4,436,401 (GBP)
Funding ID EP/V011863/1 
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 01/2021 
End 12/2024
 
Description Understanding inter-kingdom and inter-microbial interactions in microbial and fungal communities - Nanoprime (University of Nottingham, Shaun Robertson)
Amount £14,880 (GBP)
Organisation University of Nottingham 
Sector Academic/University
Country United Kingdom
Start 11/2019 
 
Description Understanding interactions between microbes in polymicrobial communities via liquid extraction surface analysis (LESA) mass spectrometry - British Mass Spectrometry Society (University of Nottingham, Shaun Robertson)
Amount £4,160 (GBP)
Organisation British Mass Spectrometry Society 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2019 
 
Description Understanding the impact on underwater cleaning on fouling control coatings (Jinju Chen)
Amount £104,900 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 08/2023 
End 09/2027
 
Description Understanding the molecular survival strategies of Acinetobacter baumannii and developing strategies to disable them.
Amount £451,305 (GBP)
Funding ID BB/V007823/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 03/2021 
End 03/2024
 
Description Unravelling the quorum sensing mechanisms in Azospirillum brasiliense Az39: one of the most used strains for agriculture in America (Miguel Camara)
Amount £12,000 (GBP)
Funding ID IEC\R2\181079 
Organisation The Royal Society 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2018 
End 12/2021
 
Description Wellcome Prime Covid-19 Research Support (Shaun Robertson)
Amount £10,306 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2022 
End 12/2022
 
Description Wellcome Prime Scholarship (Veeren Chauhan)
Amount £5,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2021 
End 07/2022
 
Title A surface-confined liposome system for early-stage evaluation of new antimicrobial molecules (Peng Bao) 
Description Many antimicrobial molecules work by disrupting cell membranes. There have been a few well-established systems/protocols for evaluation of this mode of action at the early stage of technology development. In particular, there is a need for a fast and sensitive evaluation of such ability directly at a surface. Here, we developed an assay that allows fast screening of a wide range of antimicrobial agents. A fluorescent leakage assay employing surface-confined liposomes could provide a fast/sensitive platform for the evaluation of new antimicrobial molecules. The antimicrobial properties of UV-powered active molecules (provided by our partner at the University of Nottingham) were tested using a surface-confined liposome leakage assay in vitro. The leakage assay employed micro-sized DOPC/DOTAP (1:1) vesicles attached to the glass surface and checked under UV exposure from the LED light source on Zeiss Image2 fluorescence microscope. The mean time constants (averaged over many individual vesicles, n>20) were found to be distinctly different for samples with and without molecules, directly demonstrating the disruptive effect of molecules on lipid membranes. 
Type Of Material Technology assay or reagent 
Year Produced 2022 
Provided To Others? No  
Impact The surface-confined liposome system provides an easy, fast, and sensitive way for the early-stage evaluation of the potential of new active molecules for antimicrobial applications. It could find wide applications in drug screening. 
 
Title Automated in-situ biofilm imaging and mechanical characterisation (Jinju Chen) 
Description We developed a uniquely designed automated in-situ testing rig to detect and monitor of marine biofilm erosion and study marine biofilm mechanical properties at meter scale. 
Type Of Material Improvements to research infrastructure 
Year Produced 2020 
Provided To Others? No  
Impact This technique enabled the new partnership with International Paint (AkzoNobel). We are in the process of applying the patent. 
 
Title Developed casting methods for creating elastomeric replicas of rigid structured surfaces with micron-level accuracy (Paul Stoodley) 
Description The research tool is a pipeline from casting real surface roughness from materials, including marine fouled surfaces, and creating materials with replicated patters and roughness with defined viscoelastic parameters in able to assess the relative influence of material viscoelasticity and roughness on marine drag. 
Type Of Material Technology assay or reagent 
Year Produced 2020 
Provided To Others? No  
Impact The data generated are currently being prepared for a manuscript and will serve as a PhD thesis chapter. 
 
Title Endoscope biofilm model. (Robin Thorn) 
Description UWE developed an Endoscope Biofilm Model, comprising of a re-circulating perfusion system with a known microbial load through a surrogate endoscope operating channel (PTFE tubing). The biofilm densities of the test bacterial species were determined following 72 hours of culture within the EBM. Viable biofilms were recovered from the EBM for all four bacterial species tested; P. aeruginosa, S. aureus, K. pneumonia and E. coli, whereby the results demonstrated the growth of reproducible biofilms. 
Type Of Material Technology assay or reagent 
Year Produced 2020 
Provided To Others? No  
Impact The development of this model has led to the successful demonstrated pf the efficacy of a Creo Medical Ltd. developed endoscope disinfection system for the treatment of bacterial biofilms within the internal lumen of PTFE tubing as a surrogate for medical endoscope operating channels. The success of this approach has led to successful follow-on funding directly from Creo Medical Ltd. 
 
Title Ex vivo lung model - optimised / UKAS-accredited implementation (Freya Harrison) 
Description In line with the aims of the grant, we have optimised and shared our ex vivo lung model. The current grant has allowed significant improvements and flexible re-optimisation of the model to make it more useful and tractable for colleagues, especially those in industry. We have successfully trained scientists from Perfectus Biomed Ltd. in the use of the model and helped them gain UKAS accreditation for its use in preclinical testing of antibiofilm agents. We have also published and open-access protocol for use of the model in antibiotic susceptibility testing (JoVE, video protocol to follow - delayed by COVID-19 restrictions). Please also refer to other sections of the ResearchFish submission for details of ongoing use and uptake, and the dedicated website at https://warwick.ac.uk/fac/sci/lifesci/people/fharrison/exvivolung. 
Type Of Material Technology assay or reagent 
Year Produced 2020 
Provided To Others? Yes  
Impact Accreditation of the model and Standard EN 1276 to ISO 17025 by our industrial collaborator Perfectus Biomed Ltd. for biocide testing on biofilms of P. aeruginosa. Now beiing used by Perfectus Biomoed Ltd. to test candidate antibiofilm agents for industrial clients. See https://perfectusbiomed.com/perfectus-biomed-elevate-method-testing-beyond-the-standard/ We have also published an open-access protocol for use of the model in antibiotic susceptibility testing for P. aeruginosa and S. aureus in JoVE (see Publications). We will continually monitor uptake of the model through the lifetime of the grant and beyond, an in particular record any concomitant reduction in animal usage by users of the model, and report on this at a later stage. 
URL https://www.jove.com/t/62187/antibiotic-efficacy-testing-an-ex-vivo-model-pseudomonas-aeruginosa
 
Title Fabrication of novel antimicrobial membrane to remove biofilm in female reproductive system (Farshid Sefat) 
Description In this research a group of scaffolds encapsulated and fabricated with a antibacterial drug and tested biologically. This scaffold remove biofilm in female reproductive system by a novel method. 
Type Of Material Biological samples 
Year Produced 2021 
Provided To Others? No  
Impact This is an ongoing experimental work and we are predicting the outcome will have significant impact on many patients who suffering from bacterial within females reproductive system. 
 
Title Image analysis protocol for quantifying surface structural deformation under hydrodynamic shear. (Paul Stoodley) 
Description Developed image analysis protocol for quantifying surface structural deformation under hydrodynamic shear from cross sectional optical coherence tomography images of the elastomeric replica surfaces. 
Type Of Material Technology assay or reagent 
Year Produced 2020 
Provided To Others? No  
Impact These data will be used in a peer reviewed manuscript and as a PhD chapter. 
 
Title Improvement of self referencing method for recording and mapping both ion and molecular activity and flux from single cells, tissues and biofilms (Peter J. Smith) 
Description Further development of the self referencing electrochemical method for detection of chemical activity or flux from living systems with high temporal and spatial fidelity. Previous a bespoke system the design brings in commercially available equipment, modified for function, and delivering higher sensitivity, control, analytics and versatility. Parllel and ongoing evolution of the solid state ultra micro sensor designs provide a more robust base for distributing the technology. 
Type Of Material Technology assay or reagent 
Year Produced 2020 
Provided To Others? Yes  
Impact Van Mooy, B.A.S., Hmelo, L.R., Fredricks, H.F., Ossolinski, J.E., Pedlera, B.E., Bogorff D.J. and Smith P.J.S. (2014) Quantitative exploration of the contribution of settlement, growth, dispersal and grazing to the accumulation of natural marine biofilms on antifouling and fouling-release coatings. Biofouling 30(2):223-236. DOI: 10.1080/08927014.2013.861422. Alavian, KN, Collis, L, Li, H, Bonanni, L, Zeng, L, Sacchetti, S, Lazrove, E, Nabili, P, Flaherty, B, Graham, M, Chen, Y, Messerli, S, Mariggio, MM, Rahner, C, McNay, E, Shore, G, Smith, PJS, Hardwick, JM and Jonas, EA 2011 Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase. Nature Cell Biol. 13, 1224-1233 doi:10.1038/ncb2330. 
URL https://www.tandfonline.com/doi/full/10.1080/08927014.2013.861422
 
Title Method to measure natural marine biofilm accumulation on artifical surfaces (Karen Tait) 
Description During this project we have made adaptions to established epifluorescence microscopy methods to allow us to measure natural microbial biofilm accumulation on artificial surfaces that have been exposed to untreated natural seawater. We have used epifluorescence techniques combined with image analysis to increase through-put and quality control associated with data capture from multiple images. This revised method will form the basis of a commercial biofilm quantification service and as such is commercially sensitive. 
Type Of Material Technology assay or reagent 
Year Produced 2020 
Provided To Others? No  
Impact We anticipate that this method will form the basis of a commercial biofilm quantification service for PML. 
 
Title Microfluidic-based models to screen formation of crystalline biofilms in urological devices (Dario Carugo) 
Description Microfluidic devices (referred to as stent-on-a-chip, SoC) were designed to replicate key flow dynamic features of a stented ureter in the presence of different types of ureteral obstruction. Dimensions mimic those of commercially available double-J stents. A replica moulding technique was employed in order to manufacture SoC devices, which employed 3D printed polylactic acid (PLA) master moulds. Devices can replicate the architecture of different urological stents and patient-specific urinary tracts. They have been employed as an in-vitro model to iterate different urological stent designs and assess whether specific device geometries could minimise deposition of bacteria over the device surface. 
Type Of Material Model of mechanisms or symptoms - in vitro 
Year Produced 2018 
Provided To Others? Yes  
Impact Novel ureteric stent designs have been developed, which have been proven to reduce particle deposition in-vitro. See following publications and patents: (1) Particle Accumulation in Ureteral Stents Is Governed by Fluid Dynamics: In Vitro Study Using a Stent-on-Chip Model (2) Reducing deposition of encrustation in ureteric stents by changing the stent architecture: A microfluidic-based investigation (3) A Microfluidic-Based Investigation of Bacterial Attachment in Ureteral Stents (* directly linked to this award) (4) Stent With Streamlined Side Holes 
URL https://www.mdpi.com/2072-666X/11/4/408/htm
 
Title Model reactor and culture system for biofilm metrology studies. 
Description We have developed a CDC reactor model system for Pseudomonas aeruginosa culture in order to carry out studies of biofilm reproducibility in partnership with LGC. 
Type Of Material Technology assay or reagent 
Year Produced 2022 
Provided To Others? No  
Impact Knowledge exchange and collaborative work in the area of biofilm metrology with industry partner LGC. 
 
Title Model system for the assessment of in-line ozone treatment in drinking water pipelines. 
Description Oxi-Tech have developed an in-line system for the delivery of ozone as a method to treat bacteria and biofilms within drinking water systems. We developed a recirculating water model system that incorporated an Oxi-cell and that was used to model water contamination by planktonic bacteria Escherichia coli, P. aeruginosa, and Legionella shakespearei. 
Type Of Material Technology assay or reagent 
Year Produced 2022 
Provided To Others? No  
Impact The Oxi-cell eradicated planktonic bacteria following 10 mins of activity. Biofilms of P. aeruginosa and L. shakespearei were grown for 48h and transferred to a model water system that contained 15m pipe between the Oxi-cell and the biofilms. Oxi-cell activity significantly reduced the percentage of live cells in L. shakespearei biofilms from 78% to 42%, and prevented the dispersal of live cells from the biofilms. These data together suggest that the Oxi-cell is effective at preventing dissemination and growth of bacterial biofilms within water systems, where it is unable to eradicate established biofilms. 
 
Title Optical imaging of wound dressings (Daimark Bennett) 
Description Development of an approach to visualise wound dressings and associated microbial biofilms using confocal microscopy. 
Type Of Material Technology assay or reagent 
Year Produced 2021 
Provided To Others? No  
Impact In preparation. 
 
Title Partial development of a novel testing rig (Karen Tait) 
Description This project has been severally impacted by Covid-19 and as such is still in its very early stages. We are in the early stages of developing a novel laboratory test rig to allow us to remotely quantify marine biofouling on a test panel. Due to the commercial interest in the project and IP agreements in place with our funders (National Biofilm Innovation Centre) it is not possible to disclose further information concerning the biofilm quantification techniques. 
Type Of Material Technology assay or reagent 
Year Produced 2020 
Provided To Others? No  
Impact None yet. 
 
Title Polymicrobial biofilm development 
Description This tool is a complex wound biofilm that can be used to assess inflammation and the effects of antimicrobials. 
Type Of Material Technology assay or reagent 
Year Produced 2022 
Provided To Others? Yes  
Impact Facilitated the methods to secure EPSRC grant 
URL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991182/
 
Title Porcine corneal explant cultures for antimicrobial drug development (Peter Monk) 
Description The corneum is a complex multi-layered tissue that is not easy to reproduce using cell lines. To avoid the use of living animals, we have developed an ex vivo model using the easily available by-product of the food industry. Infection with bacteria or fungi requires abrasion of the corneal epithelial layer, usually a requirement in vivo. Infection of the explants recapitulates infection in vivo, and appears similar to that seen in human corneal explants. 
Type Of Material Model of mechanisms or symptoms - in vitro 
Year Produced 2019 
Provided To Others? No  
Impact We will shortly be creating a video methods publication to allow other groups to use this method. 
 
Title Porcine skin explant model of infection using Staphylococcus aureus and Pseudomonas aeruginosa 
Description The skin explant model developed for this project a. allowed us to evaluate antimicrobial drug efficacy against biofilm infection. 
Type Of Material Technology assay or reagent 
Year Produced 2021 
Provided To Others? Yes  
Impact The model allowed us to assess Destiny Pharma's novel antimicrobial compound for efficacy against biofilm-associated infection - the compound was highly effective at killing biofilms formed by clinical S. aureus strains in the pig skin explant model. 
 
Title Rapid single-step fluorescence detection using aptamer beacon (Sourav Ghosh) 
Description The assay involves an aptamer beacon, which acts like a fluorescence switch. The aptamer fluorescence is turned off in its original state. In presence of the target species, the aptamer undergoes a change in configuration, which turns on the fluorescence. The change in intensity of fluorescence suggests quantitative detection of the target species. The method is application to a broad range of biomolecules (proteins, lipid, carbohydrates) and biological particles (fungus, spores, bacteria and virus). 
Type Of Material Technology assay or reagent 
Year Produced 2021 
Provided To Others? No  
Impact Success validation has led to clinical evaluation projects in point of care wound diagnosis (from wound swabs) and COVID-19 diagnosis from saliva. 
 
Title Reagents to monitor biofilm assays in vivo in C. elegans 
Description Reagents to monitor biofilm assays in vivo in C. elegans tested and validated. Work to improve reagents and methods ongoing in the lab. 
Type Of Material Technology assay or reagent 
Year Produced 2022 
Provided To Others? Yes  
Impact None yet but work is continued to achieve impact. 
 
Title Rotating Spiral Bioreactor (Jordan MacInnes) 
Description The prototype reactor developed in the project allows interaction between beds of microbial particles and media solutions in a controlled and therefore tractable manner. 
Type Of Material Improvements to research infrastructure 
Year Produced 2021 
Provided To Others? No  
Impact The device has already allowed precise investigation of reaction rates in microbial particle beds as a function of microbial type. The same will be true for catalytic particles of any kind. 
 
Title Standard method for growing simulated dental plaque biofilms for safety and efficacy testing using modifications of CDC and ASTM standard methods (Paul Stoodley) 
Description Biofilm communities grown from human saliva on hydroxyapatite coupons in the CDC reactor were identified through 16S sequencing and included the presence of key taxa including Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria and Fusobacteria which form the healthy core oral microbiome, including aerobes, anaerobes and unculturable species. Over an 8 day time course we observe changes to the composition of the microbiomes within the model bioreactor systems. To test this hypothesis, we utilized the commonly used antimicrobial compound chlorhexidine. Chlorhexidine was applied to bioreactor biofilms for 2 weeks resulting in significant differences in taxa composition compared to both the Control treatment and . These observations indicate that the model developed is a suitable tool for the investigation of the oral microbiome and may be valuable in determining the impact of active compounds and antimicrobial technologies on the oral microbiome, facilitating the improved development of oral healthcare products. A publication is in preparation. 
Type Of Material Technology assay or reagent 
Year Produced 2020 
Provided To Others? No  
Impact The method has potential for adoption by dental companies for testing dental hygiene products in vitro. 
 
Title Use of HS-AFM as a tool for biofilm monitoring (Michael Allen) 
Description High Speed Atomic Force Microscopy was successfully developed as a tool for assaying and analysing the structural features of biofilms. Various solid substrata which could be used in membrane bioreactors were assayed including isotactic polypropylene, polypropylene, polyethylene, polyamide and polystyrene. 
Type Of Material Technology assay or reagent 
Year Produced 2019 
Provided To Others? No  
Impact Following incubation in an aqueous environment, we could confirm and monitor biofilm formation with nanoscale resolution.Indeed, in addition to whole cellular observations ranging from larger microalgal diatom cells and bacteria, we could successfully observe what we believe to extracellular polysaccharide coating plastic surfaces. This was achieved in both air and liquid environments, the latter in particular raising the possibility of utilising this technique for non-destructive assessment of biofilm formation in the future. Independent software developments during the course of this project have allowed for the real time stitching of raster pattern generated images, providing SEM scale imagery, but delivering nanoscale resolution.Following the successful trial of the MMBR system, biofilms were monitored with the new SOP developed herein, providing HS-AFM data showing colonisation of the 'mesh' utilised. Interestingly, cells were observed to adhere to the surface elements of the individual membrane fibres, as well as being corralled in to the intervening spaces of the structure. Further work could determine the rate of colonisation and how repeated harvesting effects biofilm structure, function and integrity. 
 
Title Using H-NMR to detect the generation of Reactive Oxygen Species (Claudio Lourenco) 
Description This technique consists in the use of H-NMR to follow the reactions taking place within a complex formulation with particular emphasis in the generation of ROS. On its own the technique can effectively detect and quantify the elements present in the mixture. By fine tuning the pH of the environment the generation of ROS can be increased and its half-life in solution increased. 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? Yes  
Impact The main impact is that it allows a quick screening and quantification of a complex mixture of ingredients within a solution. It can be extremely valuable to compare new formulations enabling the researcher to test the reactants efficacy in the early stages of product development saving costs and time on not so good formulations. 
 
Title Viability status: inability of viability kits to assess damage from ozone-treated Listeria monocytogenes (Nicola Holden) 
Description Qualitative assessment of Listeria monocytogenes (Lmo) viability in biofilms was made with Lmo biofilms stained with the commercial LIVE/DEAD BacLight kit and imaged by microscopy, mounted on polylysine-coated slides. Initially, an in vitro test was performed with a 1:1 mixture of Lmo killed with 70% isopropyl alcohol: live cells cultured in TSB, and it was possible to detect both live and dead cells at the proportions expected. Detailed examination of the slides using con-focal microscopy showed two distinct layers of Lmo cells. To investigate this phenomenon, the Lmo cells were co-stained with another nuclei acid stain DAPI, and a membrane stain (FM 1-43). There appeared to be two types of debris: one stained with SYTO9 and close to the coverslip and another stained with DAPI and close to the microscope slide. The DAPI-stained debris near the slide associated with the membrane dye (FM 1-43), suggesting that lipids that may have altered the density or adhesive properties of DAPI. It is possible that staining with SYTO9 may competitively prevent binding of DAPI, explaining why it wasn't uniform. Live/Dead staining was then performed on Lmo biofilms in situ on stainless steel (SS) discs, +/- ozone treatment. It appeared that the ozone-treatment had a minimal effect on cell viability since only a very low proportion of Lmo were stained with propidium iodide in comparison to untreated SS disc biofilms that contained a 'natural' population of dead cells. Therefore, the stains were validated in situ by treatment of Lmo on SS discs with 70 % isopropyl alcohol for 1 hour, which resulted in a high proportion of dead cells, as expected. However, treatment with 3 % hydrogen peroxide for 30 minutes only yielded a small proportion of dead cells. Yet, Lmo viable plate counts decreased by ~ 2 orders of magnitude after treatment with just 2000 ppm (0.2 %). Therefore, there was a large discrepancy in viability as reported by the Live/Dead staining kit for peroxide or ozone treatments compared to viability as assessed by CFU. It was apparent that the PI dye was not able to enter ozone/peroxide-treated cells. 
Type Of Material Physiological assessment or outcome measure 
Year Produced 2019 
Provided To Others? No  
Impact The main outcome is that we are now much better informed on whether commercial kits provide correct answers to quantify viable cells and we know that it is not possible to use this approach to assess viability of ozone or peroxide-treated biofilms. Although the kits work well for other physiological stresses that result in cell death / reduced viability, the one we tested (most commonly used) was unable to accurately quantify viability from ozone or H2O2 treated cells. This has implications for food safety risk assessments since reactive oxygen (in various forms) is used commercially as a bactericidal agent. Our data was accumulated from an experimental set-up that reflected Listeria contamination in food processing settings, i.e. at low temperature and allowing biofilm formation to occur on stainless steel surfaces. We show that if the commercial kits are used for quantification of viability, and hence to calculate the extent of die-off following treatment, they would not be accurate and could over-estimate the extent of kill / die-off. In turn, this would provide mis-leading information on the efficacy of the treatment in food safety settings. 
 
Title Workflow for genomic assessment of microbially influenced corrosion 
Description The team have developed expertise in field based DNA sequencing and the use of the Nanopore sequencing platform for energy sector samples. Furthermore, the secondment has facilitate the development of industry links, both in the UK and internationally through DNV GL's global research team. 
Type Of Material Technology assay or reagent 
Year Produced 2023 
Provided To Others? No  
Impact The FTMA application has allowed knowledge exchange between NBIC researchers and renewable energy industries and infrastructure that will be required for the energy transition. This has involved working with DNV who provide access to bacterial corrosion samples, and have assets such as wind farms and pipeline digs and are who are familiar with the industries standardisation processes. 
 
Title YouSeq The ONE 16S NGS kit 
Description Create a ready to sequence 16S Library in one closed tube reaction. The ONE 16S NGS kit contains all of the reagents necessary to create a ready-to-sequence NGS library in minutes. In a breakthrough kit format, the user simply performs one closed tube qPCR reaction. The variable regions V3/4 are targeted, amplified and adapters are added in a single reaction. The quantitative PCR read out simultaneously quantifies each library so they can be pooled precisely. Then a simple bead-clean completes the workflow. After sequencing, the data can then be loaded on to our cloud for rapid analysis. A detailed report is typically returned within 15 minutes. 
Type Of Material Technology assay or reagent 
Year Produced 2019 
Provided To Others? Yes  
Impact This product was developed during an NBIC funded secondment. 
URL https://youseq.com/product/the-one-16s-ngs-kit/8
 
Title Experimental model for pre-clinical screening of urological devices (Dario Carugo) 
Description The research model comprises a microfluidic-based mimic of the stented proximal urinary tract, which can be integrated with optical/fluorescence microscopy to determine the spatio-temporal evolution of encrustation in urological devices during product development. 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? Yes  
Impact Models could be potentially employed as an alternative to animal models, in the process of iteration and pre-clinical assessment of innovative ureteric stent designs. It specifically enables investigation of the effect of urinary flow dynamics, stent's architecture, and material properties on the initiation of bacteria/crystal deposition and biofilm formation. 
URL https://www.mdpi.com/2072-666X/11/4/408
 
Title Grant data from 01POC18027 (Samantha McLean) 
Description Data arising from the PoC grant, raw data files have been uploaded to Zenodo.org. This is a closed dataset until publication, at which time it will be published in accordance with the journal requirements. Access to this data can be requested by contacting samantha.mclean@ntu.ac.uk. 
Type Of Material Database/Collection of data 
Year Produced 2021 
Provided To Others? No  
Impact N/A 
 
Title Model for reaction in a rotating spiral bioreactor (Jordan MacInnes) 
Description The mathematical model provides a consistent detailed representation of the mass transfer and reaction within a microbial bed in a rotating spiral channel. The model allows rapid determination of optimum reactor operation once a small number of bed properties are determined empirically. 
Type Of Material Computer model/algorithm 
Year Produced 2021 
Provided To Others? No  
Impact We are currently using the model to understand optimisation of catalytic particle reaction in our prototype spiral bioreactor. 
 
Title National Biofilms Innovation Centre Data and Resource Index 
Description Most Universities within the NBIC consortium already have large data storage facilities and the capacity to assign unique and permanent Digital Object Identifiers. The NBIC Universities will provide mechanisms and services for storage, backup, registration, deposit, retention and preservation of research data assets in support of current and future access, during and after completion of research projects. All NBIC partners will be required to agree to store all data, whether published or unpublished, in their institutional repositories or authorised storage facilities. NBIC are in a unique position to create data sharing policies and workflows for biofilm data. Metadata records for the data (and published outputs) generated by the consortium will be maintained by NBIC. In accordance with this, the data will be archived from a minimum of ten years after publication or last access, whichever is longer. This register includes reference to the relevant DOIs and points of contact to ensure data access is easily managed. Data will be accompanied by contextual information to enable secondary users to gain access to details on the origin or manipulation of the data to avoid misinterpretation or misuse. Future users of the data will be bound by data sharing agreements. Where suitable a licence (for example Creative Commons) can be applied to data deposited in the repository. 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? Yes  
Impact We are continuing to develop a cultural shift towards ensuring the availability of unpublished data across the NBIC consortium. We have held a workshop on data and software sustainability and are moving towards developing a community platform available to all partners. https://www.software.ac.uk/blog/2019-12-16-2019-national-biofilms-innovation-centre-workshop 
 
Title OM model development (Angela Oates) 
Description 1. Development and Validation of Osteomyelitis Biofilm Infection Model-stable and reproducible growth of S.aureus biofilm on HA discs 2. Optimisation of porous bone cement-rations of carboxymethyl cellulose (CMC) gel and smartset bone cement to generate porous bone barriers 
Type Of Material Database/Collection of data 
Year Produced 2021 
Provided To Others? No  
Impact Development of static model which stimulated porous bone in osteo enabled the exploration of plasma penetration through this barrier and measure its efficacy against propergated biofilms. Parameters of plasma doing could then be optimised. 
 
Title PlasmaTec Plasma testing data (Angela Oates) 
Description Viable count data or zone of inhibition size on s. aureus planktonic and biofilm populations 1.Treatment Time and Flow Rate Parameter Testing on Planktonic Populations-s. aureus 1,3 and 5 mins at 15w and flow 5slm 2. Flow rate optimisation -1cm distance 15w power settings 300s treatment-2.5,3.7,5 slm flow rate 3. PlasmaTec testing against Colony biofilms-biofilm age 1hr, 2hr, 4hr,6hr and 24hr 4. Hydroxyapatite Disk Biofilms Direct Dosing-biofilm age 2,4,6and24hr treated for 300s 15w, 5slm flow at 1cm distance 5. Hydroxyapatite Disk Biofilms Direct Dosing. pulses of 1min for a treatment of 5 mins 6. Treatment Time and Flow Rate Parameter Testing on Planktonic Populations (5cm distance) 7. Temperature evaluation 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? No  
Impact Evaluation of the efficacy of plasma from the device and identification of temperature effect. 
 
Title Raw sequence data: Influence of phosphate dosing on biofilms development on lead in chlorinated drinking water bioreactors (Isabel Doutelero) 
Description Raw sequence data that support the findings of this study have been deposited in NCBI library as a Sequence Read Archive (SRA) with the accession code PRJNA663268 (https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA663268). 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? Yes  
Impact Better understanding of the practice of phosphate dosing for water companies in the UK. 
URL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585443/
 
Title Steriplas Penetration and Efficacy Plasma in the OM Biofilm Infection Model and Bone (Angela Oates) 
Description Viable counts 1. Penetration and Efficacy Plasma in the OM Biofilm Infection Model-24hr biofilms + porous bone cement. Plasma dosing occurred at 24hr (10 minutes) which was repeated after 2hr. single v double dosing 2.Temperature changes in response to plasma -evaluation of additional parameter to assess if this is contributing to effect seen 3.Demonstration of Plasma Penetration Through Porous Bone Cement-comparison between porous bone cement, bone cement and plastic barrier 4.Preliminary Testing of the Efficacy of Plasma Treatment on Osteomyelitis Biofilms-Bone used in place of porous bone cement barrier in OM infection model 5. Preliminary Testing of the Efficacy of Plasma Treatment on Osteomyelitis Biofilms-Drilled bone used in place of porous bone cement barrier in OM infection model 
Type Of Material Database/Collection of data 
Year Produced 2021 
Provided To Others? No  
Impact Understanding of of the role biological mater in plasma penetration and efficacy. 
 
Title Steriplas Plasma doing optimisation (Angela Oates) 
Description Viable counts of 1. Effect of Plasma on Planktonic Populations and Hydroxyapatite Biofilms using current treatment settings-against 0hr, 5hr and 24hr biofilms 2.Evaluation of the frequency of Treatment: 10 Minute Dosing vs Multiple Dosing against 24hr biofilms. (1) single dose: 10 minutes plasma dosing at 24hrs, (2) Double dose: 10 minutes plasma dosing at 24hrs, repeated 2 hours later and (3) Triple dose: 10 minutes plasma dosing at 24hrs, repeated 2hr and 4hr. 
Type Of Material Database/Collection of data 
Year Produced 2021 
Provided To Others? No  
Impact Optimisation of dosing strategy to be testing in model and bone. Data shared with partner company. 
 
Title Wound biofilm volatile compound database 
Description The project has resulted in the generation of data sets related to the development of the sensor response of the Altered Carbon sensor array to key microbial volatiles emanating from wound biofilms. 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? No  
Impact This proof-of-concept study has resulted in identification of a suitable Altered Carbon graphene sensor array, that with further refinement and tuning has the potential to lead to development of a sensor array capable of discriminating between P. aeruginosa, S. aureus and S. pyogenes biofilms and sterile control samples. This work lays the foundation for development of a sensor system that can be applied to identification of these bacterial species in a clinical setting, and funding is now being sought to exploit these study findings. 
 
Description 20ALERT Live 3D Confocal Imaging in real time with high throughput, multipoint, targeted acquisition and AI-assisted quantification (Kim Hardie and Miguel Camara) 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC)
Country United Kingdom 
Sector Public 
PI Contribution BBSRC funding reference BB/V019414/1.
Collaborator Contribution Joint funding.
Impact Capabilities in cell, tissue and material engineering and bioprinting in 2D and 3D require next level analytical platforms. These span the length-scales of macro- (cell behaviours, physical attributes) to micro- and nano-scale. The latter includes protein crystallisation and high field NMR optimised for challenging systems (proteins / RNA / lipids etc). Our systems have capabilities such as high sensitivity cryogenically cooled probes, solid-state magic angle spinning (Ultrafast spinning upto 65 KHz), reaction monitoring and automaton for screening.
Start Year 2021
 
Description 20ALERT Live 3D Confocal Imaging in real time with high throughput, multipoint, targeted acquisition and AI-assisted quantification (Kim Hardie and Miguel Camara) 
Organisation University of Nottingham
Country United Kingdom 
Sector Academic/University 
PI Contribution BBSRC funding reference BB/V019414/1.
Collaborator Contribution Joint funding.
Impact Capabilities in cell, tissue and material engineering and bioprinting in 2D and 3D require next level analytical platforms. These span the length-scales of macro- (cell behaviours, physical attributes) to micro- and nano-scale. The latter includes protein crystallisation and high field NMR optimised for challenging systems (proteins / RNA / lipids etc). Our systems have capabilities such as high sensitivity cryogenically cooled probes, solid-state magic angle spinning (Ultrafast spinning upto 65 KHz), reaction monitoring and automaton for screening.
Start Year 2021
 
Description 3M collaborative research project (Miguel Camara) 
Organisation 3M
Country United States 
Sector Private 
PI Contribution Confidential
Collaborator Contribution Confidential
Impact Ongoing research
Start Year 2018
 
Description A joint workshop between the UK's National Biofilm Innovation Centre and the West African Centre for Cell Biology of Infectious Pathogens (Miguel Camara) 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC)
Country United Kingdom 
Sector Public 
PI Contribution This award will allow us to establish a new synergistic partnership between the UK's National Biofilm Innovation Centre (NBIC) and the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) in Ghana. Biofilms are implicated in some of the most critical global challenges and have significant economic impact across multiple sectors. They are a leading cause of chronic infections and antimicrobial resistance (AMR), described in June 2021 by G7 Health Ministers as a "silent pandemic"1 and the cause of at least 700,000 deaths globally each year. This is predicated to rise to 10M deaths a year and cost US$100Tn in world GDP by 2050 if no action is taken2. In the UK, biofilm-mediated chronic infections are estimated to cost the NHS £7.2Bn per annum3. NBIC represents a fusion of world-class research and industry to deliver breakthrough technologies in the control and exploitation of biofilms. Established in 2017, it is an interdisciplinary centre, bringing together 4 lead and 59 associate UK universities and their infrastructure, and support from a growing industry hub of over 250 companies (SME to multinational) across multiple sectors where biofilms offer both problems and opportunities. Given their global importance, NBIC is strongly committed to establishing new international partnerships to bring together the wide and diverse range of perspectives, needs and expertise required to address biofilm-related challenges. WACCBIP is one of the World Bank's Centres of Excellence at the University of Ghana. It was founded in 2013 and is led by faculty from the Department of Biochemistry, Cell and Molecular Biology and the Noguchi Memorial Institute for Medical Research (NMIMR) The centre conducts applied research into the biology and pathogenesis of tropical diseases and aims to increase research and innovation by enhancing collaboration among biomedical scientists and industry leaders across Africa.
Collaborator Contribution Full partnership.
Impact None yet
Start Year 2022
 
Description A joint workshop between the UK's National Biofilm Innovation Centre and the West African Centre for Cell Biology of Infectious Pathogens (Miguel Camara) 
Organisation Medicines Discovery Catapult
Country United Kingdom 
Sector Private 
PI Contribution This award will allow us to establish a new synergistic partnership between the UK's National Biofilm Innovation Centre (NBIC) and the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) in Ghana. Biofilms are implicated in some of the most critical global challenges and have significant economic impact across multiple sectors. They are a leading cause of chronic infections and antimicrobial resistance (AMR), described in June 2021 by G7 Health Ministers as a "silent pandemic"1 and the cause of at least 700,000 deaths globally each year. This is predicated to rise to 10M deaths a year and cost US$100Tn in world GDP by 2050 if no action is taken2. In the UK, biofilm-mediated chronic infections are estimated to cost the NHS £7.2Bn per annum3. NBIC represents a fusion of world-class research and industry to deliver breakthrough technologies in the control and exploitation of biofilms. Established in 2017, it is an interdisciplinary centre, bringing together 4 lead and 59 associate UK universities and their infrastructure, and support from a growing industry hub of over 250 companies (SME to multinational) across multiple sectors where biofilms offer both problems and opportunities. Given their global importance, NBIC is strongly committed to establishing new international partnerships to bring together the wide and diverse range of perspectives, needs and expertise required to address biofilm-related challenges. WACCBIP is one of the World Bank's Centres of Excellence at the University of Ghana. It was founded in 2013 and is led by faculty from the Department of Biochemistry, Cell and Molecular Biology and the Noguchi Memorial Institute for Medical Research (NMIMR) The centre conducts applied research into the biology and pathogenesis of tropical diseases and aims to increase research and innovation by enhancing collaboration among biomedical scientists and industry leaders across Africa.
Collaborator Contribution Full partnership.
Impact None yet
Start Year 2022
 
Description A joint workshop between the UK's National Biofilm Innovation Centre and the West African Centre for Cell Biology of Infectious Pathogens (Miguel Camara) 
Organisation National Biofilms Innovation Centre
Sector Private 
PI Contribution This award will allow us to establish a new synergistic partnership between the UK's National Biofilm Innovation Centre (NBIC) and the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) in Ghana. Biofilms are implicated in some of the most critical global challenges and have significant economic impact across multiple sectors. They are a leading cause of chronic infections and antimicrobial resistance (AMR), described in June 2021 by G7 Health Ministers as a "silent pandemic"1 and the cause of at least 700,000 deaths globally each year. This is predicated to rise to 10M deaths a year and cost US$100Tn in world GDP by 2050 if no action is taken2. In the UK, biofilm-mediated chronic infections are estimated to cost the NHS £7.2Bn per annum3. NBIC represents a fusion of world-class research and industry to deliver breakthrough technologies in the control and exploitation of biofilms. Established in 2017, it is an interdisciplinary centre, bringing together 4 lead and 59 associate UK universities and their infrastructure, and support from a growing industry hub of over 250 companies (SME to multinational) across multiple sectors where biofilms offer both problems and opportunities. Given their global importance, NBIC is strongly committed to establishing new international partnerships to bring together the wide and diverse range of perspectives, needs and expertise required to address biofilm-related challenges. WACCBIP is one of the World Bank's Centres of Excellence at the University of Ghana. It was founded in 2013 and is led by faculty from the Department of Biochemistry, Cell and Molecular Biology and the Noguchi Memorial Institute for Medical Research (NMIMR) The centre conducts applied research into the biology and pathogenesis of tropical diseases and aims to increase research and innovation by enhancing collaboration among biomedical scientists and industry leaders across Africa.
Collaborator Contribution Full partnership.
Impact None yet
Start Year 2022
 
Description A joint workshop between the UK's National Biofilm Innovation Centre and the West African Centre for Cell Biology of Infectious Pathogens (Miguel Camara) 
Organisation NovaBiotics Ltd, UK
Country United Kingdom 
Sector Private 
PI Contribution This award will allow us to establish a new synergistic partnership between the UK's National Biofilm Innovation Centre (NBIC) and the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) in Ghana. Biofilms are implicated in some of the most critical global challenges and have significant economic impact across multiple sectors. They are a leading cause of chronic infections and antimicrobial resistance (AMR), described in June 2021 by G7 Health Ministers as a "silent pandemic"1 and the cause of at least 700,000 deaths globally each year. This is predicated to rise to 10M deaths a year and cost US$100Tn in world GDP by 2050 if no action is taken2. In the UK, biofilm-mediated chronic infections are estimated to cost the NHS £7.2Bn per annum3. NBIC represents a fusion of world-class research and industry to deliver breakthrough technologies in the control and exploitation of biofilms. Established in 2017, it is an interdisciplinary centre, bringing together 4 lead and 59 associate UK universities and their infrastructure, and support from a growing industry hub of over 250 companies (SME to multinational) across multiple sectors where biofilms offer both problems and opportunities. Given their global importance, NBIC is strongly committed to establishing new international partnerships to bring together the wide and diverse range of perspectives, needs and expertise required to address biofilm-related challenges. WACCBIP is one of the World Bank's Centres of Excellence at the University of Ghana. It was founded in 2013 and is led by faculty from the Department of Biochemistry, Cell and Molecular Biology and the Noguchi Memorial Institute for Medical Research (NMIMR) The centre conducts applied research into the biology and pathogenesis of tropical diseases and aims to increase research and innovation by enhancing collaboration among biomedical scientists and industry leaders across Africa.
Collaborator Contribution Full partnership.
Impact None yet
Start Year 2022
 
Description A joint workshop between the UK's National Biofilm Innovation Centre and the West African Centre for Cell Biology of Infectious Pathogens (Miguel Camara) 
Organisation University of Ghana
Department West Africa Centre for Cell Biology of Infectious Pathogens
Country Ghana 
Sector Academic/University 
PI Contribution This award will allow us to establish a new synergistic partnership between the UK's National Biofilm Innovation Centre (NBIC) and the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) in Ghana. Biofilms are implicated in some of the most critical global challenges and have significant economic impact across multiple sectors. They are a leading cause of chronic infections and antimicrobial resistance (AMR), described in June 2021 by G7 Health Ministers as a "silent pandemic"1 and the cause of at least 700,000 deaths globally each year. This is predicated to rise to 10M deaths a year and cost US$100Tn in world GDP by 2050 if no action is taken2. In the UK, biofilm-mediated chronic infections are estimated to cost the NHS £7.2Bn per annum3. NBIC represents a fusion of world-class research and industry to deliver breakthrough technologies in the control and exploitation of biofilms. Established in 2017, it is an interdisciplinary centre, bringing together 4 lead and 59 associate UK universities and their infrastructure, and support from a growing industry hub of over 250 companies (SME to multinational) across multiple sectors where biofilms offer both problems and opportunities. Given their global importance, NBIC is strongly committed to establishing new international partnerships to bring together the wide and diverse range of perspectives, needs and expertise required to address biofilm-related challenges. WACCBIP is one of the World Bank's Centres of Excellence at the University of Ghana. It was founded in 2013 and is led by faculty from the Department of Biochemistry, Cell and Molecular Biology and the Noguchi Memorial Institute for Medical Research (NMIMR) The centre conducts applied research into the biology and pathogenesis of tropical diseases and aims to increase research and innovation by enhancing collaboration among biomedical scientists and industry leaders across Africa.
Collaborator Contribution Full partnership.
Impact None yet
Start Year 2022
 
Description A joint workshop between the UK's National Biofilm Innovation Centre and the West African Centre for Cell Biology of Infectious Pathogens (Miguel Camara) 
Organisation University of Nottingham
Country United Kingdom 
Sector Academic/University 
PI Contribution This award will allow us to establish a new synergistic partnership between the UK's National Biofilm Innovation Centre (NBIC) and the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) in Ghana. Biofilms are implicated in some of the most critical global challenges and have significant economic impact across multiple sectors. They are a leading cause of chronic infections and antimicrobial resistance (AMR), described in June 2021 by G7 Health Ministers as a "silent pandemic"1 and the cause of at least 700,000 deaths globally each year. This is predicated to rise to 10M deaths a year and cost US$100Tn in world GDP by 2050 if no action is taken2. In the UK, biofilm-mediated chronic infections are estimated to cost the NHS £7.2Bn per annum3. NBIC represents a fusion of world-class research and industry to deliver breakthrough technologies in the control and exploitation of biofilms. Established in 2017, it is an interdisciplinary centre, bringing together 4 lead and 59 associate UK universities and their infrastructure, and support from a growing industry hub of over 250 companies (SME to multinational) across multiple sectors where biofilms offer both problems and opportunities. Given their global importance, NBIC is strongly committed to establishing new international partnerships to bring together the wide and diverse range of perspectives, needs and expertise required to address biofilm-related challenges. WACCBIP is one of the World Bank's Centres of Excellence at the University of Ghana. It was founded in 2013 and is led by faculty from the Department of Biochemistry, Cell and Molecular Biology and the Noguchi Memorial Institute for Medical Research (NMIMR) The centre conducts applied research into the biology and pathogenesis of tropical diseases and aims to increase research and innovation by enhancing collaboration among biomedical scientists and industry leaders across Africa.
Collaborator Contribution Full partnership.
Impact None yet
Start Year 2022
 
Description Agent Energy and HVB PoC (Eileen Yu) 
Organisation Argent Energy
Country United Kingdom 
Sector Private 
PI Contribution Through this collaboration, the aim of this research is to develop an optimised MES process with enhanced selectivity for high-value long-chain carbohydrates (C4-C8) production.
Collaborator Contribution Argent Energy will contribute in several ways for this project as a research partner. This includes providing: • Information on effluent waste gas enriched with CO2, and effluent organic waste streams; • Advice on research questions and directions for the project; • Staff time in project evaluation and taking part in project review meetings, • Access to site visits and relevant on-site data.
Impact Secured a BBSRC High value Biorenewables PoC funding with the project Enhance selectivity for high value bioproducts from CO2 and waste organics through microbial electrosynthesis.
Start Year 2021
 
Description Agent Energy and HVB PoC (Eileen Yu) 
Organisation Loughborough University
Country United Kingdom 
Sector Academic/University 
PI Contribution Through this collaboration, the aim of this research is to develop an optimised MES process with enhanced selectivity for high-value long-chain carbohydrates (C4-C8) production.
Collaborator Contribution Argent Energy will contribute in several ways for this project as a research partner. This includes providing: • Information on effluent waste gas enriched with CO2, and effluent organic waste streams; • Advice on research questions and directions for the project; • Staff time in project evaluation and taking part in project review meetings, • Access to site visits and relevant on-site data.
Impact Secured a BBSRC High value Biorenewables PoC funding with the project Enhance selectivity for high value bioproducts from CO2 and waste organics through microbial electrosynthesis.
Start Year 2021
 
Description An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) 
Organisation AlgiPharma
Country Norway 
Sector Private 
PI Contribution NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods.
Collaborator Contribution The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada.
Impact No outputs yet.
Start Year 2021
 
Description An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods.
Collaborator Contribution The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada.
Impact No outputs yet.
Start Year 2021
 
Description An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) 
Organisation Cystic Fibrosis Foundation
Country United States 
Sector Charity/Non Profit 
PI Contribution NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods.
Collaborator Contribution The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada.
Impact No outputs yet.
Start Year 2021
 
Description An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) 
Organisation Cystic Fibrosis Trust
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods.
Collaborator Contribution The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada.
Impact No outputs yet.
Start Year 2021
 
Description An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) 
Organisation Georgia Institute of Technology
Country United States 
Sector Academic/University 
PI Contribution NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods.
Collaborator Contribution The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada.
Impact No outputs yet.
Start Year 2021
 
Description An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) 
Organisation Liverpool Heart and Chest Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods.
Collaborator Contribution The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada.
Impact No outputs yet.
Start Year 2021
 
Description An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) 
Organisation Manchester University NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods.
Collaborator Contribution The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada.
Impact No outputs yet.
Start Year 2021
 
Description An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) 
Organisation Medicines Discovery Catapult
Country United Kingdom 
Sector Private 
PI Contribution NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods.
Collaborator Contribution The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada.
Impact No outputs yet.
Start Year 2021
 
Description An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods.
Collaborator Contribution The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada.
Impact No outputs yet.
Start Year 2021
 
Description An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) 
Organisation University of Laval
Country Canada 
Sector Academic/University 
PI Contribution NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods.
Collaborator Contribution The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada.
Impact No outputs yet.
Start Year 2021
 
Description An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) 
Organisation University of Liverpool
Country United Kingdom 
Sector Academic/University 
PI Contribution NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods.
Collaborator Contribution The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada.
Impact No outputs yet.
Start Year 2021
 
Description An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) 
Organisation University of Warwick
Country United Kingdom 
Sector Academic/University 
PI Contribution NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods.
Collaborator Contribution The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada.
Impact No outputs yet.
Start Year 2021
 
Description Anti biofilm lactam technology 
Organisation Unilever
Country United Kingdom 
Sector Private 
PI Contribution prior knowledge on biofilm and anti-biofilm protocols and related microbiology. chemical synthesis and bacterial strains.
Collaborator Contribution discussion of project processes, provision of reagents, industrial placement
Impact not yet
Start Year 2019
 
Description Areas of energy and resource recovery during environmental processes such as wastewater treatment and reuse (Mohamed Mamlouk) 
Organisation Newcastle University
Country United Kingdom 
Sector Academic/University 
PI Contribution Ideas and discussion of possible joint projects.
Collaborator Contribution Host visitor and materials supply.
Impact Multi-disciplinary linking biology , electrochemistry and civil engineering.
Start Year 2020
 
Description Areas of energy and resource recovery during environmental processes such as wastewater treatment and reuse (Mohamed Mamlouk) 
Organisation Princeton University
Country United States 
Sector Academic/University 
PI Contribution Ideas and discussion of possible joint projects.
Collaborator Contribution Host visitor and materials supply.
Impact Multi-disciplinary linking biology , electrochemistry and civil engineering.
Start Year 2020
 
Description Assessment and optimisation of probiotic therapeutics against bacterial vaginosis biofilms (Ryan Kean) 
Organisation Ferring Pharmaceuticals
Country Switzerland 
Sector Private 
PI Contribution The data generated from NBIC POC 04POC21-235 has been used to secure £51,977 in funding from Ferring Pharmaceuticals to Glasgow Caledonian University, to investigate probiotic therapies against the BV model which was designed in this project. It is anticipated that future work packages will be follow on from this initial 5-month project.
Collaborator Contribution Contract research.
Impact None yet.
Start Year 2022
 
Description Assessment and optimisation of probiotic therapeutics against bacterial vaginosis biofilms (Ryan Kean) 
Organisation Glasgow Caledonian University
Country United Kingdom 
Sector Academic/University 
PI Contribution The data generated from NBIC POC 04POC21-235 has been used to secure £51,977 in funding from Ferring Pharmaceuticals to Glasgow Caledonian University, to investigate probiotic therapies against the BV model which was designed in this project. It is anticipated that future work packages will be follow on from this initial 5-month project.
Collaborator Contribution Contract research.
Impact None yet.
Start Year 2022
 
Description BBSRC CTP application (Paulina Rakowska) 
Organisation 5D Health Protection Group Ltd
Country United Kingdom 
Sector Private 
PI Contribution Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000.
Collaborator Contribution NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB.
Impact Consortium awarded funds for 15 PhDs. Award around £1.5 million.
Start Year 2020
 
Description BBSRC CTP application (Paulina Rakowska) 
Organisation BP (British Petroleum)
Country United Kingdom 
Sector Private 
PI Contribution Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000.
Collaborator Contribution NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB.
Impact Consortium awarded funds for 15 PhDs. Award around £1.5 million.
Start Year 2020
 
Description BBSRC CTP application (Paulina Rakowska) 
Organisation Chilled Food Association
Country United Kingdom 
Sector Private 
PI Contribution Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000.
Collaborator Contribution NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB.
Impact Consortium awarded funds for 15 PhDs. Award around £1.5 million.
Start Year 2020
 
Description BBSRC CTP application (Paulina Rakowska) 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000.
Collaborator Contribution NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB.
Impact Consortium awarded funds for 15 PhDs. Award around £1.5 million.
Start Year 2020
 
Description BBSRC CTP application (Paulina Rakowska) 
Organisation Industrial Biotechnology Innovation Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000.
Collaborator Contribution NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB.
Impact Consortium awarded funds for 15 PhDs. Award around £1.5 million.
Start Year 2020
 
Description BBSRC CTP application (Paulina Rakowska) 
Organisation Kohler Co
Country United States 
Sector Private 
PI Contribution Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000.
Collaborator Contribution NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB.
Impact Consortium awarded funds for 15 PhDs. Award around £1.5 million.
Start Year 2020
 
Description BBSRC CTP application (Paulina Rakowska) 
Organisation Smith and Nephew
Country United Kingdom 
Sector Private 
PI Contribution Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000.
Collaborator Contribution NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB.
Impact Consortium awarded funds for 15 PhDs. Award around £1.5 million.
Start Year 2020
 
Description BBSRC CTP application (Paulina Rakowska) 
Organisation Unilever
Country United Kingdom 
Sector Private 
PI Contribution Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000.
Collaborator Contribution NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB.
Impact Consortium awarded funds for 15 PhDs. Award around £1.5 million.
Start Year 2020
 
Description BBSRC Global Partnering Award - collaborative proposal between NBIC and India Biofilm Society (Paulina Rakowska) 
Organisation Regional Centre for Biotechnology
Country India 
Sector Public 
PI Contribution Developed and submitted collaborative proposal to the BBSRC International Partnering Awards: India Partnering Award: Building globally leading partnership between India and UK's biofilm innovation centres. Collaboration between NBIC and India Biofilms Society. funding sought: £30000.
Collaborator Contribution Co-developed the proposal with intended in-kind contribution of £30000.
Impact Submitted proposal - unsuccessful.
Start Year 2020
 
Description BBSRC Global Partnering Award - collaborative proposal between NBIC and India Biofilm Society (Paulina Rakowska) 
Organisation SASTRA University
Country India 
Sector Academic/University 
PI Contribution Developed and submitted collaborative proposal to the BBSRC International Partnering Awards: India Partnering Award: Building globally leading partnership between India and UK's biofilm innovation centres. Collaboration between NBIC and India Biofilms Society. funding sought: £30000.
Collaborator Contribution Co-developed the proposal with intended in-kind contribution of £30000.
Impact Submitted proposal - unsuccessful.
Start Year 2020
 
Description BBSRC Global Partnering Award - collaborative proposal between NBIC and India Biofilm Society (Paulina Rakowska) 
Organisation Savitribai Phule Pune University
Country India 
Sector Academic/University 
PI Contribution Developed and submitted collaborative proposal to the BBSRC International Partnering Awards: India Partnering Award: Building globally leading partnership between India and UK's biofilm innovation centres. Collaboration between NBIC and India Biofilms Society. funding sought: £30000.
Collaborator Contribution Co-developed the proposal with intended in-kind contribution of £30000.
Impact Submitted proposal - unsuccessful.
Start Year 2020
 
Description BBSRC Global Partnering Award - collaborative proposal between NBIC and India Biofilm Society (Paulina Rakowska) 
Organisation Tripura University
Country India 
Sector Academic/University 
PI Contribution Developed and submitted collaborative proposal to the BBSRC International Partnering Awards: India Partnering Award: Building globally leading partnership between India and UK's biofilm innovation centres. Collaboration between NBIC and India Biofilms Society. funding sought: £30000.
Collaborator Contribution Co-developed the proposal with intended in-kind contribution of £30000.
Impact Submitted proposal - unsuccessful.
Start Year 2020
 
Description BBSRC and MRC Ageing Across the Lifecourse Networks (Peter Smith) 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC)
Country United Kingdom 
Sector Public 
PI Contribution This is a BBSRC funded project reference BB/W018284/1. MyAge will break down the silos associated with reductionist research and bring together non-overlapping expertise of researchers, industrialists and stakeholders from muscle research, me-tabolism, regenerative medicine, genomics, epigenetics, maths, data and social sciences, health inequity, biotech and pharma to understand the mechanistic pathways of muscle development, differentiation and decline. Although considerable research has focused on the better understand-ing of the determinants of muscle ageing, the complexity of the ageing process itself requires an innovative research approach that shifts away from studying single systems in isolation towards an integrative and holistic understanding of muscle ageing where multidimensional molecular, physio-logical, organism and population level research is combined. This approach aligns strongly with rec-ommendations in The Physiological Society's report, "Growing older, better". MyAge will develop a ROADMAP that seeks to inform policy and UKRI funding calls.
Collaborator Contribution In partnership with stakeholders and industry partners we will explore interventions as well as therapeutic and lifestyle modifications that impact the progression of muscle differentiation and decline from a cellular and functional perspective. MyAge will gather researchers with expertise in regenerative biology, epigenetics, single cell analysis, nanotechnology, electrophysiology, molecular phenotyping, mitochondrial function, inflammation, endocrinology, organoid culture, performance, human ageing cohorts, and social impact. Using various model systems from nematodes to humans, the network will uncover how the molecular and metabolic landscape of myofibers, SC and non-SC progenitors and muscle tissue architecture change with ageing and through exposures to different environmental stimuli. We will integrate this knowledge with epidemiological, nutritional, societal and health inequity and inequality data. Using fMRI to image muscle during exercise will allow us to investigate the physiological basis of anabolic resistance With the latest advances in topological analysis, we will integrate complex, high dimensional data sets to unravel the fundamental mecha-nisms of muscle ageing and to define how the environmental factors though the life course affect muscle cell physiology, ageing and life course trajectory. MyAge is a new network of individual members, organisations and partners who have not previously worked together in this manner. It represents a new synthesis of disciplines. Within our membership there are pre-existing networks dealing with particular specialties, for exam-ple CMAR, (29 members from Birmingham and 22 from Nottingham). Additional networks of inves-tigators are CIMA, the Southampton Lifecourse Epidemiology Centre, the BRC Nutrition and Lifecourse theme and the IfLS. The latter has a membership of 350 investigators crossing the STEM subjects, Medicine, Health and Sociology. Bringing these groups together, alongside our individual members and partners, societies and enterprise, has never been done before. This novelty of inter-action will expedite the generation of new insights, pathways and strategies to address the chal-lenges of ageing. Although MyAge will focus on muscle ageing, our members and approach will add value to, and learn from, the proposed macro-coordination of the Ageing networks.
Impact None yet.
Start Year 2022
 
Description BBSRC and MRC Ageing Across the Lifecourse Networks (Peter Smith) 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution This is a BBSRC funded project reference BB/W018284/1. MyAge will break down the silos associated with reductionist research and bring together non-overlapping expertise of researchers, industrialists and stakeholders from muscle research, me-tabolism, regenerative medicine, genomics, epigenetics, maths, data and social sciences, health inequity, biotech and pharma to understand the mechanistic pathways of muscle development, differentiation and decline. Although considerable research has focused on the better understand-ing of the determinants of muscle ageing, the complexity of the ageing process itself requires an innovative research approach that shifts away from studying single systems in isolation towards an integrative and holistic understanding of muscle ageing where multidimensional molecular, physio-logical, organism and population level research is combined. This approach aligns strongly with rec-ommendations in The Physiological Society's report, "Growing older, better". MyAge will develop a ROADMAP that seeks to inform policy and UKRI funding calls.
Collaborator Contribution In partnership with stakeholders and industry partners we will explore interventions as well as therapeutic and lifestyle modifications that impact the progression of muscle differentiation and decline from a cellular and functional perspective. MyAge will gather researchers with expertise in regenerative biology, epigenetics, single cell analysis, nanotechnology, electrophysiology, molecular phenotyping, mitochondrial function, inflammation, endocrinology, organoid culture, performance, human ageing cohorts, and social impact. Using various model systems from nematodes to humans, the network will uncover how the molecular and metabolic landscape of myofibers, SC and non-SC progenitors and muscle tissue architecture change with ageing and through exposures to different environmental stimuli. We will integrate this knowledge with epidemiological, nutritional, societal and health inequity and inequality data. Using fMRI to image muscle during exercise will allow us to investigate the physiological basis of anabolic resistance With the latest advances in topological analysis, we will integrate complex, high dimensional data sets to unravel the fundamental mecha-nisms of muscle ageing and to define how the environmental factors though the life course affect muscle cell physiology, ageing and life course trajectory. MyAge is a new network of individual members, organisations and partners who have not previously worked together in this manner. It represents a new synthesis of disciplines. Within our membership there are pre-existing networks dealing with particular specialties, for exam-ple CMAR, (29 members from Birmingham and 22 from Nottingham). Additional networks of inves-tigators are CIMA, the Southampton Lifecourse Epidemiology Centre, the BRC Nutrition and Lifecourse theme and the IfLS. The latter has a membership of 350 investigators crossing the STEM subjects, Medicine, Health and Sociology. Bringing these groups together, alongside our individual members and partners, societies and enterprise, has never been done before. This novelty of inter-action will expedite the generation of new insights, pathways and strategies to address the chal-lenges of ageing. Although MyAge will focus on muscle ageing, our members and approach will add value to, and learn from, the proposed macro-coordination of the Ageing networks.
Impact None yet.
Start Year 2022
 
Description BBSRC and MRC Ageing Across the Lifecourse Networks (Peter Smith) 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution This is a BBSRC funded project reference BB/W018284/1. MyAge will break down the silos associated with reductionist research and bring together non-overlapping expertise of researchers, industrialists and stakeholders from muscle research, me-tabolism, regenerative medicine, genomics, epigenetics, maths, data and social sciences, health inequity, biotech and pharma to understand the mechanistic pathways of muscle development, differentiation and decline. Although considerable research has focused on the better understand-ing of the determinants of muscle ageing, the complexity of the ageing process itself requires an innovative research approach that shifts away from studying single systems in isolation towards an integrative and holistic understanding of muscle ageing where multidimensional molecular, physio-logical, organism and population level research is combined. This approach aligns strongly with rec-ommendations in The Physiological Society's report, "Growing older, better". MyAge will develop a ROADMAP that seeks to inform policy and UKRI funding calls.
Collaborator Contribution In partnership with stakeholders and industry partners we will explore interventions as well as therapeutic and lifestyle modifications that impact the progression of muscle differentiation and decline from a cellular and functional perspective. MyAge will gather researchers with expertise in regenerative biology, epigenetics, single cell analysis, nanotechnology, electrophysiology, molecular phenotyping, mitochondrial function, inflammation, endocrinology, organoid culture, performance, human ageing cohorts, and social impact. Using various model systems from nematodes to humans, the network will uncover how the molecular and metabolic landscape of myofibers, SC and non-SC progenitors and muscle tissue architecture change with ageing and through exposures to different environmental stimuli. We will integrate this knowledge with epidemiological, nutritional, societal and health inequity and inequality data. Using fMRI to image muscle during exercise will allow us to investigate the physiological basis of anabolic resistance With the latest advances in topological analysis, we will integrate complex, high dimensional data sets to unravel the fundamental mecha-nisms of muscle ageing and to define how the environmental factors though the life course affect muscle cell physiology, ageing and life course trajectory. MyAge is a new network of individual members, organisations and partners who have not previously worked together in this manner. It represents a new synthesis of disciplines. Within our membership there are pre-existing networks dealing with particular specialties, for exam-ple CMAR, (29 members from Birmingham and 22 from Nottingham). Additional networks of inves-tigators are CIMA, the Southampton Lifecourse Epidemiology Centre, the BRC Nutrition and Lifecourse theme and the IfLS. The latter has a membership of 350 investigators crossing the STEM subjects, Medicine, Health and Sociology. Bringing these groups together, alongside our individual members and partners, societies and enterprise, has never been done before. This novelty of inter-action will expedite the generation of new insights, pathways and strategies to address the chal-lenges of ageing. Although MyAge will focus on muscle ageing, our members and approach will add value to, and learn from, the proposed macro-coordination of the Ageing networks.
Impact None yet.
Start Year 2022
 
Description BBSRC and MRC Ageing Across the Lifecourse Networks (Peter Smith) 
Organisation University of Nottingham
Country United Kingdom 
Sector Academic/University 
PI Contribution This is a BBSRC funded project reference BB/W018284/1. MyAge will break down the silos associated with reductionist research and bring together non-overlapping expertise of researchers, industrialists and stakeholders from muscle research, me-tabolism, regenerative medicine, genomics, epigenetics, maths, data and social sciences, health inequity, biotech and pharma to understand the mechanistic pathways of muscle development, differentiation and decline. Although considerable research has focused on the better understand-ing of the determinants of muscle ageing, the complexity of the ageing process itself requires an innovative research approach that shifts away from studying single systems in isolation towards an integrative and holistic understanding of muscle ageing where multidimensional molecular, physio-logical, organism and population level research is combined. This approach aligns strongly with rec-ommendations in The Physiological Society's report, "Growing older, better". MyAge will develop a ROADMAP that seeks to inform policy and UKRI funding calls.
Collaborator Contribution In partnership with stakeholders and industry partners we will explore interventions as well as therapeutic and lifestyle modifications that impact the progression of muscle differentiation and decline from a cellular and functional perspective. MyAge will gather researchers with expertise in regenerative biology, epigenetics, single cell analysis, nanotechnology, electrophysiology, molecular phenotyping, mitochondrial function, inflammation, endocrinology, organoid culture, performance, human ageing cohorts, and social impact. Using various model systems from nematodes to humans, the network will uncover how the molecular and metabolic landscape of myofibers, SC and non-SC progenitors and muscle tissue architecture change with ageing and through exposures to different environmental stimuli. We will integrate this knowledge with epidemiological, nutritional, societal and health inequity and inequality data. Using fMRI to image muscle during exercise will allow us to investigate the physiological basis of anabolic resistance With the latest advances in topological analysis, we will integrate complex, high dimensional data sets to unravel the fundamental mecha-nisms of muscle ageing and to define how the environmental factors though the life course affect muscle cell physiology, ageing and life course trajectory. MyAge is a new network of individual members, organisations and partners who have not previously worked together in this manner. It represents a new synthesis of disciplines. Within our membership there are pre-existing networks dealing with particular specialties, for exam-ple CMAR, (29 members from Birmingham and 22 from Nottingham). Additional networks of inves-tigators are CIMA, the Southampton Lifecourse Epidemiology Centre, the BRC Nutrition and Lifecourse theme and the IfLS. The latter has a membership of 350 investigators crossing the STEM subjects, Medicine, Health and Sociology. Bringing these groups together, alongside our individual members and partners, societies and enterprise, has never been done before. This novelty of inter-action will expedite the generation of new insights, pathways and strategies to address the chal-lenges of ageing. Although MyAge will focus on muscle ageing, our members and approach will add value to, and learn from, the proposed macro-coordination of the Ageing networks.
Impact None yet.
Start Year 2022
 
Description BBSRC and MRC Ageing Across the Lifecourse Networks (Peter Smith) 
Organisation University of Southampton
Country United Kingdom 
Sector Academic/University 
PI Contribution This is a BBSRC funded project reference BB/W018284/1. MyAge will break down the silos associated with reductionist research and bring together non-overlapping expertise of researchers, industrialists and stakeholders from muscle research, me-tabolism, regenerative medicine, genomics, epigenetics, maths, data and social sciences, health inequity, biotech and pharma to understand the mechanistic pathways of muscle development, differentiation and decline. Although considerable research has focused on the better understand-ing of the determinants of muscle ageing, the complexity of the ageing process itself requires an innovative research approach that shifts away from studying single systems in isolation towards an integrative and holistic understanding of muscle ageing where multidimensional molecular, physio-logical, organism and population level research is combined. This approach aligns strongly with rec-ommendations in The Physiological Society's report, "Growing older, better". MyAge will develop a ROADMAP that seeks to inform policy and UKRI funding calls.
Collaborator Contribution In partnership with stakeholders and industry partners we will explore interventions as well as therapeutic and lifestyle modifications that impact the progression of muscle differentiation and decline from a cellular and functional perspective. MyAge will gather researchers with expertise in regenerative biology, epigenetics, single cell analysis, nanotechnology, electrophysiology, molecular phenotyping, mitochondrial function, inflammation, endocrinology, organoid culture, performance, human ageing cohorts, and social impact. Using various model systems from nematodes to humans, the network will uncover how the molecular and metabolic landscape of myofibers, SC and non-SC progenitors and muscle tissue architecture change with ageing and through exposures to different environmental stimuli. We will integrate this knowledge with epidemiological, nutritional, societal and health inequity and inequality data. Using fMRI to image muscle during exercise will allow us to investigate the physiological basis of anabolic resistance With the latest advances in topological analysis, we will integrate complex, high dimensional data sets to unravel the fundamental mecha-nisms of muscle ageing and to define how the environmental factors though the life course affect muscle cell physiology, ageing and life course trajectory. MyAge is a new network of individual members, organisations and partners who have not previously worked together in this manner. It represents a new synthesis of disciplines. Within our membership there are pre-existing networks dealing with particular specialties, for exam-ple CMAR, (29 members from Birmingham and 22 from Nottingham). Additional networks of inves-tigators are CIMA, the Southampton Lifecourse Epidemiology Centre, the BRC Nutrition and Lifecourse theme and the IfLS. The latter has a membership of 350 investigators crossing the STEM subjects, Medicine, Health and Sociology. Bringing these groups together, alongside our individual members and partners, societies and enterprise, has never been done before. This novelty of inter-action will expedite the generation of new insights, pathways and strategies to address the chal-lenges of ageing. Although MyAge will focus on muscle ageing, our members and approach will add value to, and learn from, the proposed macro-coordination of the Ageing networks.
Impact None yet.
Start Year 2022
 
Description Britest collaboration on cleaning (William Zimmerman) 
Organisation Britest
Country United Kingdom 
Sector Private 
PI Contribution Britest is a non-profit service company set up by it industrial consortium membership for the intensification of batch processing, drawing from biopharma, fine chemicals, agrichemicals and other process industries for its base. Britest has an ongoing initiative for better process cleaning, decontamination, disinfection and related technologies. Professor Joan Cordiner who joined the University of Sheffield and I presented our portfolio of cleaning related research activities to the Britest Symposium 21,22 January 2021 this year. The acting MD of Britest is liaising with the membership on our behalf to collaborate on EPSRC and InnovateUK grant proposals. Professor Cordiner's industrial background includes building expert systems for scheduling industrial plant / unit operation cleaning regimes.
Collaborator Contribution We are currently consortium building. We have a two page executive summary of the advances and research goals for the joint industry-academe programme, including the possibility of testing on the University of Sheffield unique £2m pilot plant tabletting facility for pharmaceutical engineering. In exchanges with industrial contacts, this is a facility that they would like to access for improving their cleaning regimes offline, i.e. not on their own production facility with valuable pharmaceuticals at full scale.
Impact Dissemination at the moment. Next major activity will be publication of the results of the NBIC funded feasibility study on biofilm removal. The final report is an excellent starting point.
Start Year 2020
 
Description Britest collaboration on cleaning (William Zimmerman) 
Organisation University of Sheffield
Country United Kingdom 
Sector Academic/University 
PI Contribution Britest is a non-profit service company set up by it industrial consortium membership for the intensification of batch processing, drawing from biopharma, fine chemicals, agrichemicals and other process industries for its base. Britest has an ongoing initiative for better process cleaning, decontamination, disinfection and related technologies. Professor Joan Cordiner who joined the University of Sheffield and I presented our portfolio of cleaning related research activities to the Britest Symposium 21,22 January 2021 this year. The acting MD of Britest is liaising with the membership on our behalf to collaborate on EPSRC and InnovateUK grant proposals. Professor Cordiner's industrial background includes building expert systems for scheduling industrial plant / unit operation cleaning regimes.
Collaborator Contribution We are currently consortium building. We have a two page executive summary of the advances and research goals for the joint industry-academe programme, including the possibility of testing on the University of Sheffield unique £2m pilot plant tabletting facility for pharmaceutical engineering. In exchanges with industrial contacts, this is a facility that they would like to access for improving their cleaning regimes offline, i.e. not on their own production facility with valuable pharmaceuticals at full scale.
Impact Dissemination at the moment. Next major activity will be publication of the results of the NBIC funded feasibility study on biofilm removal. The final report is an excellent starting point.
Start Year 2020
 
Description Building a globally leading partnership between the UK National Biofilms Innovation Centre and Argentina (Miguel Camara) 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC)
Country United Kingdom 
Sector Public 
PI Contribution Microbes are key in sustainable crop production but there are many unknowns on how populations of bacteria and fungi communities known as biofilms influence plant behaviour and impact on plant nutrition and protection, soil quality,bioremediation and climate change. This award brings together researchers/industry from the UK's National Biofilms Innovation Centre and Argentina to address this knowledge gap and improve agricultural productivity in both countries reducing the use of chemical treatments and their environmental impact. The objectives are to:-Bring together complementary academic/industrial expertise from these countries on the exploitation of biofilms in agriculture-Identify the key knowledge gaps and research challenges in this area of agricultural impact.-Develop a white paper that establishes priority research areas to address these gaps.-Create future research collaborations for the use of biofilms in crop production between the Uk and Argentina.
Collaborator Contribution Specific activities that will arise as outcomes from this collaborative programme include: •A joint UK-Argentine forumto share knowledge and facilitate future collaborations•Production and publication ofa 'white paper'on the current state of art, practices, challenges and research priority areasin the utilisation of plant -microbe interactionsin crop production in the UK, Argentina and globally.•Research internships for UK early career researchersto visitArgentinian institutions. These will be achieved through targeted calls subsidised by this award and based on the research priorities outlined in the white paper. The UKand Argentinianinstitutions will seekfurther funding to host Argentinian early career researchers. •Ajoint NBIC-SAMIGE/SAIB webinar seriesopenedto the international research community with talks from academic and industrial representatives to increase awareness of the research and innovation activities carried out within this collaborative partnership.•The establishment of a long-term strategic research programmebetween NBIC and the Argentinian partners enabling theco-development of jointfunding proposals.
Impact None yet.
Start Year 2021
 
Description Building a globally leading partnership between the UK National Biofilms Innovation Centre and Argentina (Miguel Camara) 
Organisation National Biofilms Innovation Centre
Sector Private 
PI Contribution Microbes are key in sustainable crop production but there are many unknowns on how populations of bacteria and fungi communities known as biofilms influence plant behaviour and impact on plant nutrition and protection, soil quality,bioremediation and climate change. This award brings together researchers/industry from the UK's National Biofilms Innovation Centre and Argentina to address this knowledge gap and improve agricultural productivity in both countries reducing the use of chemical treatments and their environmental impact. The objectives are to:-Bring together complementary academic/industrial expertise from these countries on the exploitation of biofilms in agriculture-Identify the key knowledge gaps and research challenges in this area of agricultural impact.-Develop a white paper that establishes priority research areas to address these gaps.-Create future research collaborations for the use of biofilms in crop production between the Uk and Argentina.
Collaborator Contribution Specific activities that will arise as outcomes from this collaborative programme include: •A joint UK-Argentine forumto share knowledge and facilitate future collaborations•Production and publication ofa 'white paper'on the current state of art, practices, challenges and research priority areasin the utilisation of plant -microbe interactionsin crop production in the UK, Argentina and globally.•Research internships for UK early career researchersto visitArgentinian institutions. These will be achieved through targeted calls subsidised by this award and based on the research priorities outlined in the white paper. The UKand Argentinianinstitutions will seekfurther funding to host Argentinian early career researchers. •Ajoint NBIC-SAMIGE/SAIB webinar seriesopenedto the international research community with talks from academic and industrial representatives to increase awareness of the research and innovation activities carried out within this collaborative partnership.•The establishment of a long-term strategic research programmebetween NBIC and the Argentinian partners enabling theco-development of jointfunding proposals.
Impact None yet.
Start Year 2021
 
Description Building a globally leading partnership between the UK National Biofilms Innovation Centre and Argentina (Miguel Camara) 
Organisation National Institute of Agricultural Technology
Country Argentina 
Sector Public 
PI Contribution Microbes are key in sustainable crop production but there are many unknowns on how populations of bacteria and fungi communities known as biofilms influence plant behaviour and impact on plant nutrition and protection, soil quality,bioremediation and climate change. This award brings together researchers/industry from the UK's National Biofilms Innovation Centre and Argentina to address this knowledge gap and improve agricultural productivity in both countries reducing the use of chemical treatments and their environmental impact. The objectives are to:-Bring together complementary academic/industrial expertise from these countries on the exploitation of biofilms in agriculture-Identify the key knowledge gaps and research challenges in this area of agricultural impact.-Develop a white paper that establishes priority research areas to address these gaps.-Create future research collaborations for the use of biofilms in crop production between the Uk and Argentina.
Collaborator Contribution Specific activities that will arise as outcomes from this collaborative programme include: •A joint UK-Argentine forumto share knowledge and facilitate future collaborations•Production and publication ofa 'white paper'on the current state of art, practices, challenges and research priority areasin the utilisation of plant -microbe interactionsin crop production in the UK, Argentina and globally.•Research internships for UK early career researchersto visitArgentinian institutions. These will be achieved through targeted calls subsidised by this award and based on the research priorities outlined in the white paper. The UKand Argentinianinstitutions will seekfurther funding to host Argentinian early career researchers. •Ajoint NBIC-SAMIGE/SAIB webinar seriesopenedto the international research community with talks from academic and industrial representatives to increase awareness of the research and innovation activities carried out within this collaborative partnership.•The establishment of a long-term strategic research programmebetween NBIC and the Argentinian partners enabling theco-development of jointfunding proposals.
Impact None yet.
Start Year 2021
 
Description Building a globally leading partnership between the UK National Biofilms Innovation Centre and Argentina (Miguel Camara) 
Organisation National Scientific and Technical Research Council (Argentina)
Country Argentina 
Sector Public 
PI Contribution Microbes are key in sustainable crop production but there are many unknowns on how populations of bacteria and fungi communities known as biofilms influence plant behaviour and impact on plant nutrition and protection, soil quality,bioremediation and climate change. This award brings together researchers/industry from the UK's National Biofilms Innovation Centre and Argentina to address this knowledge gap and improve agricultural productivity in both countries reducing the use of chemical treatments and their environmental impact. The objectives are to:-Bring together complementary academic/industrial expertise from these countries on the exploitation of biofilms in agriculture-Identify the key knowledge gaps and research challenges in this area of agricultural impact.-Develop a white paper that establishes priority research areas to address these gaps.-Create future research collaborations for the use of biofilms in crop production between the Uk and Argentina.
Collaborator Contribution Specific activities that will arise as outcomes from this collaborative programme include: •A joint UK-Argentine forumto share knowledge and facilitate future collaborations•Production and publication ofa 'white paper'on the current state of art, practices, challenges and research priority areasin the utilisation of plant -microbe interactionsin crop production in the UK, Argentina and globally.•Research internships for UK early career researchersto visitArgentinian institutions. These will be achieved through targeted calls subsidised by this award and based on the research priorities outlined in the white paper. The UKand Argentinianinstitutions will seekfurther funding to host Argentinian early career researchers. •Ajoint NBIC-SAMIGE/SAIB webinar seriesopenedto the international research community with talks from academic and industrial representatives to increase awareness of the research and innovation activities carried out within this collaborative partnership.•The establishment of a long-term strategic research programmebetween NBIC and the Argentinian partners enabling theco-development of jointfunding proposals.
Impact None yet.
Start Year 2021
 
Description Building a globally leading partnership between the UK National Biofilms Innovation Centre and Argentina (Miguel Camara) 
Organisation National University of Rosario
Country Argentina 
Sector Academic/University 
PI Contribution Microbes are key in sustainable crop production but there are many unknowns on how populations of bacteria and fungi communities known as biofilms influence plant behaviour and impact on plant nutrition and protection, soil quality,bioremediation and climate change. This award brings together researchers/industry from the UK's National Biofilms Innovation Centre and Argentina to address this knowledge gap and improve agricultural productivity in both countries reducing the use of chemical treatments and their environmental impact. The objectives are to:-Bring together complementary academic/industrial expertise from these countries on the exploitation of biofilms in agriculture-Identify the key knowledge gaps and research challenges in this area of agricultural impact.-Develop a white paper that establishes priority research areas to address these gaps.-Create future research collaborations for the use of biofilms in crop production between the Uk and Argentina.
Collaborator Contribution Specific activities that will arise as outcomes from this collaborative programme include: •A joint UK-Argentine forumto share knowledge and facilitate future collaborations•Production and publication ofa 'white paper'on the current state of art, practices, challenges and research priority areasin the utilisation of plant -microbe interactionsin crop production in the UK, Argentina and globally.•Research internships for UK early career researchersto visitArgentinian institutions. These will be achieved through targeted calls subsidised by this award and based on the research priorities outlined in the white paper. The UKand Argentinianinstitutions will seekfurther funding to host Argentinian early career researchers. •Ajoint NBIC-SAMIGE/SAIB webinar seriesopenedto the international research community with talks from academic and industrial representatives to increase awareness of the research and innovation activities carried out within this collaborative partnership.•The establishment of a long-term strategic research programmebetween NBIC and the Argentinian partners enabling theco-development of jointfunding proposals.
Impact None yet.
Start Year 2021
 
Description Building a globally leading partnership between the UK National Biofilms Innovation Centre and Argentina (Miguel Camara) 
Organisation National University of Río Cuarto
Country Argentina 
Sector Academic/University 
PI Contribution Microbes are key in sustainable crop production but there are many unknowns on how populations of bacteria and fungi communities known as biofilms influence plant behaviour and impact on plant nutrition and protection, soil quality,bioremediation and climate change. This award brings together researchers/industry from the UK's National Biofilms Innovation Centre and Argentina to address this knowledge gap and improve agricultural productivity in both countries reducing the use of chemical treatments and their environmental impact. The objectives are to:-Bring together complementary academic/industrial expertise from these countries on the exploitation of biofilms in agriculture-Identify the key knowledge gaps and research challenges in this area of agricultural impact.-Develop a white paper that establishes priority research areas to address these gaps.-Create future research collaborations for the use of biofilms in crop production between the Uk and Argentina.
Collaborator Contribution Specific activities that will arise as outcomes from this collaborative programme include: •A joint UK-Argentine forumto share knowledge and facilitate future collaborations•Production and publication ofa 'white paper'on the current state of art, practices, challenges and research priority areasin the utilisation of plant -microbe interactionsin crop production in the UK, Argentina and globally.•Research internships for UK early career researchersto visitArgentinian institutions. These will be achieved through targeted calls subsidised by this award and based on the research priorities outlined in the white paper. The UKand Argentinianinstitutions will seekfurther funding to host Argentinian early career researchers. •Ajoint NBIC-SAMIGE/SAIB webinar seriesopenedto the international research community with talks from academic and industrial representatives to increase awareness of the research and innovation activities carried out within this collaborative partnership.•The establishment of a long-term strategic research programmebetween NBIC and the Argentinian partners enabling theco-development of jointfunding proposals.
Impact None yet.
Start Year 2021
 
Description Building a globally leading partnership between the UK National Biofilms Innovation Centre and Argentina (Miguel Camara) 
Organisation University of La Plata
Country Argentina 
Sector Academic/University 
PI Contribution Microbes are key in sustainable crop production but there are many unknowns on how populations of bacteria and fungi communities known as biofilms influence plant behaviour and impact on plant nutrition and protection, soil quality,bioremediation and climate change. This award brings together researchers/industry from the UK's National Biofilms Innovation Centre and Argentina to address this knowledge gap and improve agricultural productivity in both countries reducing the use of chemical treatments and their environmental impact. The objectives are to:-Bring together complementary academic/industrial expertise from these countries on the exploitation of biofilms in agriculture-Identify the key knowledge gaps and research challenges in this area of agricultural impact.-Develop a white paper that establishes priority research areas to address these gaps.-Create future research collaborations for the use of biofilms in crop production between the Uk and Argentina.
Collaborator Contribution Specific activities that will arise as outcomes from this collaborative programme include: •A joint UK-Argentine forumto share knowledge and facilitate future collaborations•Production and publication ofa 'white paper'on the current state of art, practices, challenges and research priority areasin the utilisation of plant -microbe interactionsin crop production in the UK, Argentina and globally.•Research internships for UK early career researchersto visitArgentinian institutions. These will be achieved through targeted calls subsidised by this award and based on the research priorities outlined in the white paper. The UKand Argentinianinstitutions will seekfurther funding to host Argentinian early career researchers. •Ajoint NBIC-SAMIGE/SAIB webinar seriesopenedto the international research community with talks from academic and industrial representatives to increase awareness of the research and innovation activities carried out within this collaborative partnership.•The establishment of a long-term strategic research programmebetween NBIC and the Argentinian partners enabling theco-development of jointfunding proposals.
Impact None yet.
Start Year 2021
 
Description COST action 
Organisation BAM Federal Institute for Materials Research and Testing
Country Germany 
Sector Public 
PI Contribution Cost-Action Euro-MIC has been accepted. We seems to have scored full marks in all categories. There were a total of 90 co-applicants worldwide and from all disciplines. This is the product of an interdisciplinary collaboration.
Collaborator Contribution Committed to join the European MIC Network-New paths for science, sustainability and standards, when proposal will be successful. Proposal Reference OC-2020-1-24906.
Impact No outcomes yet.
Start Year 2021
 
Description Clinical collaboration with Salford Royal NHS Foundation Trust (Mohamed El Mohtadi) 
Organisation Manchester Metropolitan University
Country United Kingdom 
Sector Academic/University 
PI Contribution Securing the FTMA has allowed me to strengthen my collaboration with 5D Health Protection Group Ltd and Manchester Metropolitan University which resulted in me obtaining a Visiting Lecturer position at MMU. The in vitro work carried out during the fellowship has attracted clinical collaborations as we are now replicating the experiments using clinical samples obtained from Salford Royal NHS Foundation Trust operated Salford Royal Hospital.
Collaborator Contribution The role of collaborators (i.e. Dr Ashworth) involves the conceptualisation of project ideas and supervision of students. This will ultimately lead to increased research outcomes and the publication of several original research articles in the near future.
Impact Submission of a grant bid to the Academy of Medical Sciences. The application is currently under review.
Start Year 2020
 
Description Clinical collaboration with Salford Royal NHS Foundation Trust (Mohamed El Mohtadi) 
Organisation Salford Royal NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Securing the FTMA has allowed me to strengthen my collaboration with 5D Health Protection Group Ltd and Manchester Metropolitan University which resulted in me obtaining a Visiting Lecturer position at MMU. The in vitro work carried out during the fellowship has attracted clinical collaborations as we are now replicating the experiments using clinical samples obtained from Salford Royal NHS Foundation Trust operated Salford Royal Hospital.
Collaborator Contribution The role of collaborators (i.e. Dr Ashworth) involves the conceptualisation of project ideas and supervision of students. This will ultimately lead to increased research outcomes and the publication of several original research articles in the near future.
Impact Submission of a grant bid to the Academy of Medical Sciences. The application is currently under review.
Start Year 2020
 
Description Collaboration on Bioinformatics with the University of Glasgow (Isabel Doutelero) 
Organisation Commonwealth Scientific and Industrial Research Organisation
Country Australia 
Sector Public 
PI Contribution The experiments run to study climate change at the U. of Sheffield will be used to develop new bioinformatics tools by Dr Umer Ijaz (Reader in bioinformtics) at the U. of Glasgow. for drinking water systems.
Collaborator Contribution Dr Ijaz will studied the use of different bioinformatics tools to study the microbial ecology of drinking water distribution systems using DNA sequencing data from Sheffield experiments.
Impact Two PhD studentships have been advertised at the University of Glasgow.
Start Year 2019
 
Description Collaboration on Bioinformatics with the University of Glasgow (Isabel Doutelero) 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution The experiments run to study climate change at the U. of Sheffield will be used to develop new bioinformatics tools by Dr Umer Ijaz (Reader in bioinformtics) at the U. of Glasgow. for drinking water systems.
Collaborator Contribution Dr Ijaz will studied the use of different bioinformatics tools to study the microbial ecology of drinking water distribution systems using DNA sequencing data from Sheffield experiments.
Impact Two PhD studentships have been advertised at the University of Glasgow.
Start Year 2019
 
Description Collaboration on Bioinformatics with the University of Glasgow (Isabel Doutelero) 
Organisation University of Sheffield
Country United Kingdom 
Sector Academic/University 
PI Contribution The experiments run to study climate change at the U. of Sheffield will be used to develop new bioinformatics tools by Dr Umer Ijaz (Reader in bioinformtics) at the U. of Glasgow. for drinking water systems.
Collaborator Contribution Dr Ijaz will studied the use of different bioinformatics tools to study the microbial ecology of drinking water distribution systems using DNA sequencing data from Sheffield experiments.
Impact Two PhD studentships have been advertised at the University of Glasgow.
Start Year 2019
 
Description Collaboration with Unilever for antibacterial surface (Xinyi Zhu) 
Organisation Unilever
Country United Kingdom 
Sector Private 
PI Contribution This project is confidentially, the details cannot be shared. Material surface characterisation has been done, and the application part is now in process.
Collaborator Contribution Input into the project.
Impact Details cannot be provided.
Start Year 2021
 
Description Collaboration with Universidad Politecnica de Valencia, Spain. (Isabel Doutelero) 
Organisation Polytechnic University of Valencia
Country Spain 
Sector Academic/University 
PI Contribution Collaboration between Isabel Douterelo with Prof Joaquin Izquierdo and Dr Silvia Carpitella, on decision making tools regarding the management of drinking water systems.
Collaborator Contribution Application of decision making tools to microbiological data from drinking water systems.
Impact One publication submitted: https://doi.org/10.3390/w12051247
Start Year 2019
 
Description Collaboration with Universidad Politecnica de Valencia, Spain. (Isabel Doutelero) 
Organisation University of Sheffield
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration between Isabel Douterelo with Prof Joaquin Izquierdo and Dr Silvia Carpitella, on decision making tools regarding the management of drinking water systems.
Collaborator Contribution Application of decision making tools to microbiological data from drinking water systems.
Impact One publication submitted: https://doi.org/10.3390/w12051247
Start Year 2019
 
Description Continued collaboration with ARM (Christopher Howe) 
Organisation Arm Limited
Country United Kingdom 
Sector Private 
PI Contribution Analysis of current generation from algal biofilms.
Collaborator Contribution Application of current generation from algal biofilms.
Impact None to date.
Start Year 2020
 
Description Continued collaboration with ARM (Christopher Howe) 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Analysis of current generation from algal biofilms.
Collaborator Contribution Application of current generation from algal biofilms.
Impact None to date.
Start Year 2020
 
Description Controlling bacterial aggregation 
Organisation Fujifilm
Department Fujifilm Diosynth Biotechnologies, UK
Country United Kingdom 
Sector Private 
PI Contribution We have made an intellectual contribution to the project and contributed a new experimental system for further investigation and potential exploitation.
Collaborator Contribution The collaborative team have brought intellectual and commercial expertise to the project, and have also linked us up to a wider collaborative group.
Impact This is an interdisciplinary project combining microbiology and molecular biology expertise with insights from soft matter physics and colloidal aggregation/self-assembly.
Start Year 2022
 
Description Creating of a working partnership between Valeport and PML (Karen Tait) 
Organisation Plymouth Marine Laboratory
Country United Kingdom 
Sector Academic/University 
PI Contribution PML aims to develop a novel laboratory testing rig to allow Valeport to remotely quantify marine biofouling on a test panel.
Collaborator Contribution Valeport has provided the infrastructure for PML.
Impact The main outcome of the project so far has been significant external commercial interest from several multinational marine industrial organisations.
Start Year 2020
 
Description Creating of a working partnership between Valeport and PML (Karen Tait) 
Organisation Valeport
Country United Kingdom 
Sector Private 
PI Contribution PML aims to develop a novel laboratory testing rig to allow Valeport to remotely quantify marine biofouling on a test panel.
Collaborator Contribution Valeport has provided the infrastructure for PML.
Impact The main outcome of the project so far has been significant external commercial interest from several multinational marine industrial organisations.
Start Year 2020
 
Description Creation of working partnership between PML and Unilever (Karen Tait) 
Organisation Plymouth Marine Laboratory
Country United Kingdom 
Sector Academic/University 
PI Contribution PML was able to provide the infrastructure and capability to test a product developed by Unilever in the marine environment with the aim of determining if it could be used as a means of deterring fouling.
Collaborator Contribution Unilever sought a partner who could test a product they had developed within the marine environment to prevent biofouling.
Impact PML has generated several data sets describing the ability of our partner's compound to prevent biofouling or biofouling related organisms from growing on a range of artificial surfaces. Also generated are several data sets describing the ability of the compound to inhibit growth of unicellular algae when the compound was in suspension in seawater.
Start Year 2019
 
Description Creation of working partnership between PML and Unilever (Karen Tait) 
Organisation Unilever
Country United Kingdom 
Sector Private 
PI Contribution PML was able to provide the infrastructure and capability to test a product developed by Unilever in the marine environment with the aim of determining if it could be used as a means of deterring fouling.
Collaborator Contribution Unilever sought a partner who could test a product they had developed within the marine environment to prevent biofouling.
Impact PML has generated several data sets describing the ability of our partner's compound to prevent biofouling or biofouling related organisms from growing on a range of artificial surfaces. Also generated are several data sets describing the ability of the compound to inhibit growth of unicellular algae when the compound was in suspension in seawater.
Start Year 2019
 
Description Development and application of a new technology for the targeted management of biofilms in human chronic wounds (Thomas Harle) 
Organisation Fourth State Medicine Ltd
Country United Kingdom 
Sector Private 
PI Contribution Full collaborative partners.
Collaborator Contribution Full collaborative partners.
Impact Continued work from the NBIC funded POC project (reference 02POC19129)
Start Year 2018
 
Description Development and application of a new technology for the targeted management of biofilms in human chronic wounds (Thomas Harle) 
Organisation Innovate UK
Country United Kingdom 
Sector Public 
PI Contribution Full collaborative partners.
Collaborator Contribution Full collaborative partners.
Impact Continued work from the NBIC funded POC project (reference 02POC19129)
Start Year 2018
 
Description Development and application of a new technology for the targeted management of biofilms in human chronic wounds (Thomas Harle) 
Organisation University of Hull
Country United Kingdom 
Sector Academic/University 
PI Contribution Full collaborative partners.
Collaborator Contribution Full collaborative partners.
Impact Continued work from the NBIC funded POC project (reference 02POC19129)
Start Year 2018
 
Description Development of Surgihoney and other compositions comprising an enzyme that is able to convert a substrate to release hydrogen peroxide as a novel biofilm-targeted topical therapy in chronic rhinosinusitis. (Jeremy Webb) 
Organisation Matoke Holdings
Country United Kingdom 
Sector Private 
PI Contribution Research.
Collaborator Contribution Funding and collaboration.
Impact Research outputs, please refer to https://journals.sagepub.com/doi/10.1177/1945892419874700.
Start Year 2018
 
Description Development of Surgihoney and other compositions comprising an enzyme that is able to convert a substrate to release hydrogen peroxide as a novel biofilm-targeted topical therapy in chronic rhinosinusitis. (Jeremy Webb) 
Organisation University of Southampton
Country United Kingdom 
Sector Academic/University 
PI Contribution Research.
Collaborator Contribution Funding and collaboration.
Impact Research outputs, please refer to https://journals.sagepub.com/doi/10.1177/1945892419874700.
Start Year 2018
 
Description Development of polymicrobial skin colonisation model 
Organisation Unilever
Country United Kingdom 
Sector Private 
PI Contribution prior knowledge on biofilms and protocol/development of skin colonisation protocols
Collaborator Contribution discussion to develop the project
Impact Barzan, G., A. Sacco, A., Mandrile, L., Giovannozzi, A.M., Brown, J., Portesi, C., Alexander, M., Williams, P., Hardie, K.R., and Rossi, A.M. (2019) New frontiers against multi-drug resistance: A Raman-based approach for detection of bacterial viability and cross-induced antibiotic resistances within 1 hour. In press Sensors and Actuators B: Chemical. Jordana-Luch, E., Gacia, V, Kingdon, A., Singh, N., Alexander, C., Williams, P., and Hardie, K.R. (2019). Development of a polymicrobial model to examine interactions between commensals and pathogens on skin. Submitted to Frontiers in Microbiology
Start Year 2015
 
Description Doctoral Training Partnership in Translational Biomedical Sciences (Mark Cragg) 
Organisation Medical Research Council (MRC)
Country United Kingdom 
Sector Public 
PI Contribution Medical Research Council (MCR) funded DTP.
Collaborator Contribution Medical Research Council (MCR) funded DTP.
Impact None yet.
Start Year 2021
 
Description Doctoral Training Partnership in Translational Biomedical Sciences (Mark Cragg) 
Organisation Queen Mary University of London
Country United Kingdom 
Sector Academic/University 
PI Contribution Medical Research Council (MCR) funded DTP.
Collaborator Contribution Medical Research Council (MCR) funded DTP.
Impact None yet.
Start Year 2021
 
Description Doctoral Training Partnership in Translational Biomedical Sciences (Mark Cragg) 
Organisation University of Southampton
Country United Kingdom 
Sector Academic/University 
PI Contribution Medical Research Council (MCR) funded DTP.
Collaborator Contribution Medical Research Council (MCR) funded DTP.
Impact None yet.
Start Year 2021
 
Description EPSRC Healthcare Technologies Programme Grant Application (Dario Carugo) 
Organisation National Biofilms Innovation Centre
Sector Private 
PI Contribution Collaborative writing EPSRC Healthcare Technologies Programme Grant Application.
Collaborator Contribution Collaborative writing EPSRC Healthcare Technologies Programme Grant Application.
Impact EP/V026623/1 (the grant application is still under review).
Start Year 2020
 
Description EPSRC IAA - Anti-Viral Surfaces and Materials (Rasmita Raval) 
Organisation Gencoa
Country United Kingdom 
Sector Private 
PI Contribution Developing anti-microbial technologies via knowledge-based design.
Collaborator Contribution Gencoa: The preparation of a range of novel antiviral surface coatings, production / test facilities and technical staff input. UKRI: Funding.
Impact Multi-disciplinary: Surface science, Chemistry, Imaging science, Microbiology.
Start Year 2020
 
Description EPSRC IAA - Anti-Viral Surfaces and Materials (Rasmita Raval) 
Organisation United Kingdom Research and Innovation
Country United Kingdom 
Sector Public 
PI Contribution Developing anti-microbial technologies via knowledge-based design.
Collaborator Contribution Gencoa: The preparation of a range of novel antiviral surface coatings, production / test facilities and technical staff input. UKRI: Funding.
Impact Multi-disciplinary: Surface science, Chemistry, Imaging science, Microbiology.
Start Year 2020
 
Description Edinburgh South Community Engagement (JC Denis) 
Organisation Edinburgh bioQuarter
Country United Kingdom 
Sector Private 
PI Contribution Contributed with funds, contacts and time for the delivery of community engagement activities to multi-deprived areas in the South of Edinburgh.
Collaborator Contribution Contributed with funds, contacts and time for the delivery of community engagement activities to multi-deprived areas in the South of Edinburgh.
Impact Delivery of multiple engagement activities.
Start Year 2018
 
Description Efficacy testing of CytaCoat antimicrobial catheter (Sandra Wilks) 
Organisation CytaCoat
Country Sweden 
Sector Private 
PI Contribution Consultancy work for CytaCoat using advanced biofilm analysis tools to demonstrate efficacy of their antimicrobial coating technology.
Collaborator Contribution Provided antimicrobial catheter for testing.
Impact None yet.
Start Year 2022
 
Description Exploring the disease-modifying potential of probiotic Bacillus subtilis in Parkinson's disease (Nicola Stanley-Wall) 
Organisation Johns Hopkins University
Department School of Medicine Johns Hopkins
Country United States 
Sector Academic/University 
PI Contribution Research grant and clinical trial paid for by grant issued by Reta Lila Weston Trust For Medical Research.
Collaborator Contribution Research grant and clinical trial paid for by grant issued by Reta Lila Weston Trust For Medical Research.
Impact None yet
Start Year 2021
 
Description Exploring the disease-modifying potential of probiotic Bacillus subtilis in Parkinson's disease (Nicola Stanley-Wall) 
Organisation Reta Lila Weston Trust For Medical Research
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Research grant and clinical trial paid for by grant issued by Reta Lila Weston Trust For Medical Research.
Collaborator Contribution Research grant and clinical trial paid for by grant issued by Reta Lila Weston Trust For Medical Research.
Impact None yet
Start Year 2021
 
Description Exploring the disease-modifying potential of probiotic Bacillus subtilis in Parkinson's disease (Nicola Stanley-Wall) 
Organisation Stavanger University Hospital
Country Norway 
Sector Hospitals 
PI Contribution Research grant and clinical trial paid for by grant issued by Reta Lila Weston Trust For Medical Research.
Collaborator Contribution Research grant and clinical trial paid for by grant issued by Reta Lila Weston Trust For Medical Research.
Impact None yet
Start Year 2021
 
Description Exploring the disease-modifying potential of probiotic Bacillus subtilis in Parkinson's disease (Nicola Stanley-Wall) 
Organisation University of Dundee
Country United Kingdom 
Sector Academic/University 
PI Contribution Research grant and clinical trial paid for by grant issued by Reta Lila Weston Trust For Medical Research.
Collaborator Contribution Research grant and clinical trial paid for by grant issued by Reta Lila Weston Trust For Medical Research.
Impact None yet
Start Year 2021
 
Description Exploring the disease-modifying potential of probiotic Bacillus subtilis in Parkinson's disease (Nicola Stanley-Wall) 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Research grant and clinical trial paid for by grant issued by Reta Lila Weston Trust For Medical Research.
Collaborator Contribution Research grant and clinical trial paid for by grant issued by Reta Lila Weston Trust For Medical Research.
Impact None yet
Start Year 2021
 
Description Feasibility test for large scale Microbial Electrolysis Cells (MEC) (Elizabeth Heidrich) 
Organisation Veolia Water Technologies
Country Italy 
Sector Private 
PI Contribution The modelling data generated here has helped predict performances for our actual pilot scale reactor, and we have secured further funding from Newcastle University impact acceleration accounts to trial the reactor set ups that were modelled. This will both validate the model outcomes and lead to a publication, but aslo provide real data on the performance of these reactors. We have partnered with Veolia who will use this performance data to input into their company software to analyse the impact that MEC technologies could have ont he energy use and resource recovery of wastewater treatment sites.
Collaborator Contribution Veolia has made a site visit to us and the pilot scale reactors to discuss the opportunities for this technology. We have had two zoom conference calls with the company to illustrate the capabilities of this modelling software, and the company have committed to doing several days of modelling for us when we have the data from the real systems to model.
Impact The original project was between maths and engineering We have secured University IAA funding.
Start Year 2022
 
Description Fellowship Enhancing the Effect of Antibiotics released from HA/ß-TCP bone grafts on Biofilm Mediated Osteomyelitis Using Quorum Sensing Inhibitors (Anirban Jyoti) 
Organisation Ceramisys
Country United Kingdom 
Sector Private 
PI Contribution Funding for this fellowship.
Collaborator Contribution Funding for this fellowship.
Impact None yet.
Start Year 2020
 
Description Fellowship Enhancing the Effect of Antibiotics released from HA/ß-TCP bone grafts on Biofilm Mediated Osteomyelitis Using Quorum Sensing Inhibitors (Anirban Jyoti) 
Organisation University of Nottingham
Country United Kingdom 
Sector Academic/University 
PI Contribution Funding for this fellowship.
Collaborator Contribution Funding for this fellowship.
Impact None yet.
Start Year 2020
 
Description Fellowship Enhancing the Effect of Antibiotics released from HA/ß-TCP bone grafts on Biofilm Mediated Osteomyelitis Using Quorum Sensing Inhibitors (Anirban Jyoti) 
Organisation University of Surrey
Department Daphne Jackson Trust
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Funding for this fellowship.
Collaborator Contribution Funding for this fellowship.
Impact None yet.
Start Year 2020
 
Description Global Challenges Research Fund (GCRF): Global-NAMRIP workshop (Kampala, Uganda) (Tim Leighton) 
Organisation Makerere University
Country Uganda 
Sector Academic/University 
PI Contribution Global Challenges Research Fund (GCRF) funding was secured by Tim Leighton to hold the 2nd Global Network for Antimicrobial Resistance and Infection Prevention Symposium.
Collaborator Contribution A jointly run symposium between Global-NAMRIP and Makerere University, Kampala, Uganda.
Impact The theme of the conference is 'Innovations towards combating antimicrobial resistance: a whole society engagement'. Delegates across a range of disciplines (healthcare, animal husbandry, food supply, water suppliers, and chemists and engineers researching new rapid diagnostic tools and therapies, and social scientists who examine our behaviour in responding to the AMR crisis) will present this 'whole society engagement'.
Start Year 2018
 
Description Global Challenges Research Fund (GCRF): Global-NAMRIP workshop (Kampala, Uganda) (Tim Leighton) 
Organisation United Kingdom Research and Innovation
Country United Kingdom 
Sector Public 
PI Contribution Global Challenges Research Fund (GCRF) funding was secured by Tim Leighton to hold the 2nd Global Network for Antimicrobial Resistance and Infection Prevention Symposium.
Collaborator Contribution A jointly run symposium between Global-NAMRIP and Makerere University, Kampala, Uganda.
Impact The theme of the conference is 'Innovations towards combating antimicrobial resistance: a whole society engagement'. Delegates across a range of disciplines (healthcare, animal husbandry, food supply, water suppliers, and chemists and engineers researching new rapid diagnostic tools and therapies, and social scientists who examine our behaviour in responding to the AMR crisis) will present this 'whole society engagement'.
Start Year 2018
 
Description Global Challenges Research Fund (GCRF): Global-NAMRIP workshop (Kampala, Uganda) (Tim Leighton) 
Organisation University of Southampton
Country United Kingdom 
Sector Academic/University 
PI Contribution Global Challenges Research Fund (GCRF) funding was secured by Tim Leighton to hold the 2nd Global Network for Antimicrobial Resistance and Infection Prevention Symposium.
Collaborator Contribution A jointly run symposium between Global-NAMRIP and Makerere University, Kampala, Uganda.
Impact The theme of the conference is 'Innovations towards combating antimicrobial resistance: a whole society engagement'. Delegates across a range of disciplines (healthcare, animal husbandry, food supply, water suppliers, and chemists and engineers researching new rapid diagnostic tools and therapies, and social scientists who examine our behaviour in responding to the AMR crisis) will present this 'whole society engagement'.
Start Year 2018
 
Description Holographic microscopy to investigate the impact of CPC on bacterial swimming motility (Morgan Alexander and Paul Williams) 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Research project titled Holographic microscopy to investigate the impact of CPC on bacterial swimming motility.
Collaborator Contribution Funding and access to facilities.
Impact Confidential
Start Year 2020
 
Description Holographic microscopy to investigate the impact of CPC on bacterial swimming motility (Morgan Alexander and Paul Williams) 
Organisation University of Southampton
Country United Kingdom 
Sector Academic/University 
PI Contribution Research project titled Holographic microscopy to investigate the impact of CPC on bacterial swimming motility.
Collaborator Contribution Funding and access to facilities.
Impact Confidential
Start Year 2020
 
Description Impact Acceleration Account 2020-22: Bioinspired Antimicrobial Surfaces (Andrew Parnell) 
Organisation Engineering and Physical Sciences Research Council (EPSRC)
Country United Kingdom 
Sector Public 
PI Contribution EPSRC provided funding for this project which is a continuation of work from the NBIC funded FTMA project (reference FTMA_20_IF_070).
Collaborator Contribution EPSRC provided funding for this project which is a continuation of work from the NBIC funded FTMA project (reference FTMA_20_IF_070).
Impact EPSRC provided funding for this project which is a continuation of work from the NBIC funded FTMA project (reference FTMA_20_IF_070).
Start Year 2021
 
Description Impact Acceleration Account 2020-22: Bioinspired Antimicrobial Surfaces (Andrew Parnell) 
Organisation University of Sheffield
Country United Kingdom 
Sector Academic/University 
PI Contribution EPSRC provided funding for this project which is a continuation of work from the NBIC funded FTMA project (reference FTMA_20_IF_070).
Collaborator Contribution EPSRC provided funding for this project which is a continuation of work from the NBIC funded FTMA project (reference FTMA_20_IF_070).
Impact EPSRC provided funding for this project which is a continuation of work from the NBIC funded FTMA project (reference FTMA_20_IF_070).
Start Year 2021
 
Description Industry partnership with LGC 
Organisation Laboratory of the Government Chemist (LGC) Ltd
Country United Kingdom 
Sector Private 
PI Contribution LGC Group, formerly the Laboratory of the Government Chemist, is an international life sciences measurement and tools company. It provides the role and duties of the UK Government Chemist, a statutory role and adviser to the government. We are working together in the metrology of biofilms, to understand the feasibility of developing new standards for molecular and 'omics approaches to measuring biofilms. We are providing the biofilm models and culture systems in order to generate biological material for the studies.
Collaborator Contribution LGC are applying in-house analytical measurements and approaches in order to understand the variability and reproducibility of biofilm assays, and the feasibility to develop new standards.
Impact Knowledge exchange in use of the CDC biofilm reactor model and in biofilm metrology.
Start Year 2021
 
Description Informal supervisor to EPSRC ICASE project (Paulina Rakowska) 
Organisation National Physical Laboratory
Country United Kingdom 
Sector Academic/University 
PI Contribution Informal supervisor to EPSRC ICASE project: Profiling the mycobacteria biofilm: a multidisciplinary mix of mutants and mass spectrometry. Collaboration between NPL (my previous employer) and the university of Surrey (Dr Suzie Hingley-wilson and Prof. Mark Chambers). Student - Winnifred Akwani. Developed collaborative programme for the studentship. Co-authored proposal and formally supervised the student as industrial supervisor until moving to NBIC. Remaining as Informal supervisor until the end of the project.
Collaborator Contribution Developed collaborative project for the studentship. Co-authored proposal and formally supervised the student as academic supervisor.
Impact None yet.
Start Year 2018
 
Description Informal supervisor to EPSRC ICASE project (Paulina Rakowska) 
Organisation University of Surrey
Country United Kingdom 
Sector Academic/University 
PI Contribution Informal supervisor to EPSRC ICASE project: Profiling the mycobacteria biofilm: a multidisciplinary mix of mutants and mass spectrometry. Collaboration between NPL (my previous employer) and the university of Surrey (Dr Suzie Hingley-wilson and Prof. Mark Chambers). Student - Winnifred Akwani. Developed collaborative programme for the studentship. Co-authored proposal and formally supervised the student as industrial supervisor until moving to NBIC. Remaining as Informal supervisor until the end of the project.
Collaborator Contribution Developed collaborative project for the studentship. Co-authored proposal and formally supervised the student as academic supervisor.
Impact None yet.
Start Year 2018
 
Description Innovate UK The Sustainable Innovation Fund: SBRI Phase 2: Covid-19 worker safety tag with social distancing warnings and contact tracing functionality - anti microbials in plastics (Steve Law) 
Organisation 5D Health Protection Group Ltd
Country United Kingdom 
Sector Private 
PI Contribution Create test pieces of the X30 substrate with the AM additive and test that the additive does not affect the hazardous area material properties - in particular surface resistivity. This is an innovative step as there are no hazardous area approved materials with AM additives on the market. Eliminating the virus from the surface of the X30 will help prevent its spread. Additionally, dispensing Cold Plasma whilst the X30 is held within a multicharger will also help prevent virus spread. Innovate UK funding reference: 10004577.
Collaborator Contribution Full collaborative partners on this research project. In kind contribution from 5D Health Protection relates to internal labour and microbiology consumables.
Impact None yet.
Start Year 2021
 
Description Innovate UK The Sustainable Innovation Fund: SBRI Phase 2: Covid-19 worker safety tag with social distancing warnings and contact tracing functionality - anti microbials in plastics (Steve Law) 
Organisation Extronics Ltd
Country United Kingdom 
Sector Private 
PI Contribution Create test pieces of the X30 substrate with the AM additive and test that the additive does not affect the hazardous area material properties - in particular surface resistivity. This is an innovative step as there are no hazardous area approved materials with AM additives on the market. Eliminating the virus from the surface of the X30 will help prevent its spread. Additionally, dispensing Cold Plasma whilst the X30 is held within a multicharger will also help prevent virus spread. Innovate UK funding reference: 10004577.
Collaborator Contribution Full collaborative partners on this research project. In kind contribution from 5D Health Protection relates to internal labour and microbiology consumables.
Impact None yet.
Start Year 2021
 
Description Innovate UK The Sustainable Innovation Fund: SBRI Phase 2: Covid-19 worker safety tag with social distancing warnings and contact tracing functionality - anti microbials in plastics (Steve Law) 
Organisation Innovate UK
Country United Kingdom 
Sector Public 
PI Contribution Create test pieces of the X30 substrate with the AM additive and test that the additive does not affect the hazardous area material properties - in particular surface resistivity. This is an innovative step as there are no hazardous area approved materials with AM additives on the market. Eliminating the virus from the surface of the X30 will help prevent its spread. Additionally, dispensing Cold Plasma whilst the X30 is held within a multicharger will also help prevent virus spread. Innovate UK funding reference: 10004577.
Collaborator Contribution Full collaborative partners on this research project. In kind contribution from 5D Health Protection relates to internal labour and microbiology consumables.
Impact None yet.
Start Year 2021
 
Description Innovate UK The Sustainable Innovation Fund: SBRI Phase 2: Covid-19 worker safety tag with social distancing warnings and contact tracing functionality - anti microbials in plastics (Steve Law) 
Organisation University of Warwick
Country United Kingdom 
Sector Academic/University 
PI Contribution Create test pieces of the X30 substrate with the AM additive and test that the additive does not affect the hazardous area material properties - in particular surface resistivity. This is an innovative step as there are no hazardous area approved materials with AM additives on the market. Eliminating the virus from the surface of the X30 will help prevent its spread. Additionally, dispensing Cold Plasma whilst the X30 is held within a multicharger will also help prevent virus spread. Innovate UK funding reference: 10004577.
Collaborator Contribution Full collaborative partners on this research project. In kind contribution from 5D Health Protection relates to internal labour and microbiology consumables.
Impact None yet.
Start Year 2021
 
Description Innovate UK The Sustainable Innovation Fund: SBRI Phase 2: Covid-19 worker safety tag with social distancing warnings and contact tracing functionality - cold plasma (Marcus Swann) 
Organisation 5D Health Protection Group Ltd
Country United Kingdom 
Sector Private 
PI Contribution Create test pieces of the X30 substrate with the AM additive and test that the additive does not affect the hazardous area material properties - in particular surface resistivity. This is an innovative step as there are no hazardous area approved materials with AM additives on the market. Eliminating the virus from the surface of the X30 will help prevent its spread. Additionally, dispensing Cold Plasma whilst the X30 is held within a multicharger will also help prevent virus spread. Innovate UK funding reference: 10004577.
Collaborator Contribution Full collaborative partners in this research project. In kind contribution from 5D Health Protection relates to internal labour and microbiology consumables.
Impact None yet.
Start Year 2021
 
Description Innovate UK The Sustainable Innovation Fund: SBRI Phase 2: Covid-19 worker safety tag with social distancing warnings and contact tracing functionality - cold plasma (Marcus Swann) 
Organisation Extronics Ltd
Country United Kingdom 
Sector Private 
PI Contribution Create test pieces of the X30 substrate with the AM additive and test that the additive does not affect the hazardous area material properties - in particular surface resistivity. This is an innovative step as there are no hazardous area approved materials with AM additives on the market. Eliminating the virus from the surface of the X30 will help prevent its spread. Additionally, dispensing Cold Plasma whilst the X30 is held within a multicharger will also help prevent virus spread. Innovate UK funding reference: 10004577.
Collaborator Contribution Full collaborative partners in this research project. In kind contribution from 5D Health Protection relates to internal labour and microbiology consumables.
Impact None yet.
Start Year 2021
 
Description Innovate UK The Sustainable Innovation Fund: SBRI Phase 2: Covid-19 worker safety tag with social distancing warnings and contact tracing functionality - cold plasma (Marcus Swann) 
Organisation Innovate UK
Country United Kingdom 
Sector Public 
PI Contribution Create test pieces of the X30 substrate with the AM additive and test that the additive does not affect the hazardous area material properties - in particular surface resistivity. This is an innovative step as there are no hazardous area approved materials with AM additives on the market. Eliminating the virus from the surface of the X30 will help prevent its spread. Additionally, dispensing Cold Plasma whilst the X30 is held within a multicharger will also help prevent virus spread. Innovate UK funding reference: 10004577.
Collaborator Contribution Full collaborative partners in this research project. In kind contribution from 5D Health Protection relates to internal labour and microbiology consumables.
Impact None yet.
Start Year 2021
 
Description Innovate UK The Sustainable Innovation Fund: SBRI Phase 2: Covid-19 worker safety tag with social distancing warnings and contact tracing functionality - cold plasma (Marcus Swann) 
Organisation University of Liverpool
Country United Kingdom 
Sector Academic/University 
PI Contribution Create test pieces of the X30 substrate with the AM additive and test that the additive does not affect the hazardous area material properties - in particular surface resistivity. This is an innovative step as there are no hazardous area approved materials with AM additives on the market. Eliminating the virus from the surface of the X30 will help prevent its spread. Additionally, dispensing Cold Plasma whilst the X30 is held within a multicharger will also help prevent virus spread. Innovate UK funding reference: 10004577.
Collaborator Contribution Full collaborative partners in this research project. In kind contribution from 5D Health Protection relates to internal labour and microbiology consumables.
Impact None yet.
Start Year 2021
 
Description Innovate UK: Anti-viral transparent adhesive protection for Touch Screens to help in the fight against COVID-19 (Rasmita Raval) 
Organisation Emerson & Renwick Limited
Country United Kingdom 
Sector Private 
PI Contribution Academic research and labs.
Collaborator Contribution Materials and subcontracting.
Impact Ongoing.
Start Year 2020
 
Description Innovate UK: Anti-viral transparent adhesive protection for Touch Screens to help in the fight against COVID-19 (Rasmita Raval) 
Organisation Gencoa
Country United Kingdom 
Sector Private 
PI Contribution Academic research and labs.
Collaborator Contribution Materials and subcontracting.
Impact Ongoing.
Start Year 2020
 
Description Innovate UK: Anti-viral transparent adhesive protection for Touch Screens to help in the fight against COVID-19 (Rasmita Raval) 
Organisation Innovate UK
Country United Kingdom 
Sector Public 
PI Contribution Academic research and labs.
Collaborator Contribution Materials and subcontracting.
Impact Ongoing.
Start Year 2020
 
Description Innovate UK: Anti-viral transparent adhesive protection for Touch Screens to help in the fight against COVID-19 (Rasmita Raval) 
Organisation Liverpool School of Tropical Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Academic research and labs.
Collaborator Contribution Materials and subcontracting.
Impact Ongoing.
Start Year 2020
 
Description Innovate UK: Anti-viral transparent adhesive protection for Touch Screens to help in the fight against COVID-19 (Rasmita Raval) 
Organisation University of Liverpool
Country United Kingdom 
Sector Academic/University 
PI Contribution Academic research and labs.
Collaborator Contribution Materials and subcontracting.
Impact Ongoing.
Start Year 2020
 
Description Intelligent Imaging Innovations, Inc. (3i) 
Organisation Intelligent Imaging Innovations Ltd
Country United Kingdom 
Sector Private 
PI Contribution As a result of the BBSRC/NBIC funding (NBIC_FTMA_P_19_2_47 and NBIC_FTMA_20_IF_083) we have established a working relationship with 3i and now have a NBIC DTP iCASE studentship that will take forward promising results from these pump priming projects.
Collaborator Contribution 3i will provide access to advanced instrumentation and placment training for the iCASE student
Impact None to date
Start Year 2023
 
Description Investigations of material science and scale up processing of anti biofilm and additive Potential application areas (non-medical) (Vannessa Goodship) 
Organisation 5D Health Protection Group Ltd
Country United Kingdom 
Sector Private 
PI Contribution Investigations of material science and scale up processing of anti biofilm and additive Potential application areas (non-medical).
Collaborator Contribution Biological testing and guidance Potential application areas (medical).
Impact Multi-disciplinary: chemistry, material science, biological science SME engagement and intern programme.
Start Year 2021
 
Description Investigations of material science and scale up processing of anti biofilm and additive Potential application areas (non-medical) (Vannessa Goodship) 
Organisation High Value Manufacturing Catapult
Country United Kingdom 
Sector Private